US20030215798A1 - High throughput fluorescence-based screening for novel enzymes - Google Patents
High throughput fluorescence-based screening for novel enzymes Download PDFInfo
- Publication number
- US20030215798A1 US20030215798A1 US08/876,276 US87627697A US2003215798A1 US 20030215798 A1 US20030215798 A1 US 20030215798A1 US 87627697 A US87627697 A US 87627697A US 2003215798 A1 US2003215798 A1 US 2003215798A1
- Authority
- US
- United States
- Prior art keywords
- dna
- cells
- clones
- enzyme
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012216 screening Methods 0.000 title claims abstract description 51
- 102000004190 Enzymes Human genes 0.000 title claims description 99
- 108090000790 Enzymes Proteins 0.000 title claims description 99
- 238000000034 method Methods 0.000 claims abstract description 119
- 239000000758 substrate Substances 0.000 claims abstract description 88
- 108020004414 DNA Proteins 0.000 claims description 175
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- -1 haloperoxidases Proteins 0.000 claims description 15
- 108090000371 Esterases Proteins 0.000 claims description 14
- 230000000975 bioactive effect Effects 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 238000002703 mutagenesis Methods 0.000 claims description 9
- 231100000350 mutagenesis Toxicity 0.000 claims description 9
- 108090001060 Lipase Proteins 0.000 claims description 8
- 102000004882 Lipase Human genes 0.000 claims description 8
- 239000004367 Lipase Substances 0.000 claims description 8
- 238000013537 high throughput screening Methods 0.000 claims description 8
- 235000019421 lipase Nutrition 0.000 claims description 8
- 102000004157 Hydrolases Human genes 0.000 claims description 7
- 108090000604 Hydrolases Proteins 0.000 claims description 7
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 6
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 6
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 230000009465 prokaryotic expression Effects 0.000 claims description 5
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 108700023418 Amidases Proteins 0.000 claims description 3
- 102000005922 amidase Human genes 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 102000016680 Dioxygenases Human genes 0.000 claims description 2
- 108010028143 Dioxygenases Proteins 0.000 claims description 2
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 2
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 2
- 108010054320 Lignin peroxidase Proteins 0.000 claims description 2
- 101710155614 Ligninase A Proteins 0.000 claims description 2
- 101710155621 Ligninase B Proteins 0.000 claims description 2
- 108010033272 Nitrilase Proteins 0.000 claims description 2
- 108010024026 Nitrile hydratase Proteins 0.000 claims description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
- 108090000340 Transaminases Proteins 0.000 claims description 2
- 102000003929 Transaminases Human genes 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 108090000531 Amidohydrolases Proteins 0.000 claims 1
- 102000004092 Amidohydrolases Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 1
- SLIWIQKBDGZFQR-PIVCGYGYSA-N n-[3-oxo-3',6'-bis[[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-1,9'-xanthene]-5-yl]dodecanamide Chemical compound C=1C(NC(=O)CCCCCCCCCCC)=CC=C2C=1C(=O)OC2(C1=CC=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C=C1OC1=C2)C1=CC=C2O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SLIWIQKBDGZFQR-PIVCGYGYSA-N 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 74
- 230000014509 gene expression Effects 0.000 abstract description 56
- 230000008569 process Effects 0.000 abstract description 33
- 150000007523 nucleic acids Chemical class 0.000 abstract description 30
- 102000039446 nucleic acids Human genes 0.000 abstract description 29
- 108020004707 nucleic acids Proteins 0.000 abstract description 29
- 238000003556 assay Methods 0.000 abstract description 15
- 230000027455 binding Effects 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 168
- 108090000623 proteins and genes Proteins 0.000 description 66
- 239000000523 sample Substances 0.000 description 53
- 239000013598 vector Substances 0.000 description 46
- 241000588724 Escherichia coli Species 0.000 description 34
- 230000007613 environmental effect Effects 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 244000005700 microbiome Species 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000010367 cloning Methods 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- ZTOBILYWTYHOJB-WBCGDKOGSA-N 3',6'-bis[[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C3(C4=CC=CC=C4C(=O)O3)C3=CC=C(O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)C=C3OC2=C1 ZTOBILYWTYHOJB-WBCGDKOGSA-N 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 15
- 108091008053 gene clusters Proteins 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000894007 species Species 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 238000010606 normalization Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 108010030975 Polyketide Synthases Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000002026 chloroform extract Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000004102 animal cell Anatomy 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
- 229940098124 cesium chloride Drugs 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000001952 enzyme assay Methods 0.000 description 5
- 229930001119 polyketide Natural products 0.000 description 5
- 125000000830 polyketide group Chemical group 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 241000617156 archaeon Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000011942 biocatalyst Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000283283 Orcinus orca Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000205091 Sulfolobus solfataricus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MWHKPYATGMFFPI-LYYZXLFJSA-N 2-naphthyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC=C2)C2=C1 MWHKPYATGMFFPI-LYYZXLFJSA-N 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101000961203 Aspergillus awamori Glucoamylase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000005486 Epoxide hydrolase Human genes 0.000 description 1
- 108020002908 Epoxide hydrolase Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 241000863422 Myxococcus xanthus Species 0.000 description 1
- IAXWSWBNKSRRKD-UHFFFAOYSA-N N,N-diethylethanamine dodecanoyl dodecanoate Chemical compound CCN(CC)CC.CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC IAXWSWBNKSRRKD-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000009670 mycobacterial growth Effects 0.000 description 1
- VJNRUQFWKRLMSL-UHFFFAOYSA-N n-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)dodecanamide Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(NC(=O)CCCCCCCCCCC)=CC=C21 VJNRUQFWKRLMSL-UHFFFAOYSA-N 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000005332 obsidian Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000006464 oxidative addition reaction Methods 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011945 regioselective hydrolysis Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000010801 sewage sludge Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 101150101324 spo gene Proteins 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
Definitions
- the present invention relates to the discovery of new bioactive molecules, such as biocatalysts.
- This invention employs high throughput cell analyzing, in particular fluorescence activated cell sorting (FACS), machines in a screening system designed for the rapid discovery of a large number of these molecules.
- FACS fluorescence activated cell sorting
- Enzymes have evolved by selective pressure to perform very specific biological functions within the milieu of a living organism, under conditions of mild temperature, pH and salt concentration.
- the non-DNA modifying enzyme activities thus far described (Enzyme Nomenclature, 1992) have been isolated from mesophilic organisms, which represent a very small fraction of the available phylogenetic diversity (Amann et al., 1995).
- the dynamic field of biocatalysis takes on a new dimension with the help of enzymes isolated from microorganisms that thrive in extreme environments. Such enzymes must function at temperatures above 100° C.
- esterases and lipases cloned and expressed from extremophilic organisms are remarkably robust, showing high activity throughout a wide range of temperatures and pHs.
- the fingerprints of five of these esterases show a diverse substrate spectrum, in addition to differences in the optimum reaction temperature.
- esterase #5 recognizes only short chain substrates while #2 only acts on long chain substrates in addition to a huge difference in the optimal reaction temperature.
- genes Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
- the genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
- the gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes, usually from 2 to 6 genes.
- a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of one or more identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated of adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
- Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization.
- Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and encoded enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins.
- the method(s) of the present invention facilitate the rapid discovery of these gene clusters in gene expression libraries.
- the present invention combines a culture-independent approach to directly clone genes encoding novel bioactivities from environmental samples with an extremely high throughput screening system designed for the rapid discovery of new biomolecules.
- the strategy begins with the construction of gene libraries which represent the genome(s) of microorganisms archived in cloning vectors that can be propagated in E. coli or other suitable prokaryotic hosts.
- “environmental libraries” which represent the collective genomes of naturally occurring microorganisms are generated.
- the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture.
- “normalization” can be performed on the environmental nucleic acid as one approach to more equally represent the DNA from all of the species present in the original sample. Normalization techniques can dramatically increase the efficiency of discovery from genomes which may represent minor constituents of the environmental sample. Normalization is preferable since at least one study has demonstrated that an organism of interest can be underrepresented by five orders of magnitude compared to the dominant species (Stetter, pers. comm.).
- Fluorescence-activated cell sorting has been primarily used in studies of human and animal cell lines and the control of cell culture processes. Fluorophore labeling of cells and measurement of the fluorescence can give quantitative data about specific target molecules or subcellular components and their distribution in the cell population. Flow cytometry can quantitate virtually any cell-associated property or cell organelle for which there is a fluorescent probe (or natural fluorescence). The parameters which can be measured have previously been of particular interest in animal cell culture.
- Flow cytometry has also been used in cloning and selection of variants from existing cell clones. This selection, however, has required stains that diffuse through cells passively, rapidly and irreversibly, with no toxic effects or other influences on metabolic or physiological processes. Since, typically, flow sorting has been used to study animal cell culture performance, physiological state of cells, and the cell cycle, one goal of cell sorting has been to keep the cells viable during and after sorting.
- Diaper and Edwards used flow cytometry to detect viable bacteria after staining with a range of fluorogenic esters including fluorescein diacetate (FDA) derivatives and CemChrome B, a proprietary stain sold commercially for the detection of viable bacteria in suspension (Diaper and Edwards, 1994). Labeled antibodies and oligonucleotide probes have also been used for these purposes.
- FDA fluorescein diacetate
- CemChrome B a proprietary stain sold commercially for the detection of viable bacteria in suspension
- lipase production was automatically assayed (turbidimetrically) in the microtiter plates, and a representative set of the most active were reisolated, cultured, and assayed conventionally (Betz et al., 1984).
- Scrienc et al. have reported a flow cytometric method for detecting cloned -galactosidase activity in the eukaryotic organism, S. cerevisiae .
- the ability of flow cytometry to make measurements on single cells means that individual cells with high levels of expression (e.g., due to gene amplification or higher plasmid copy number) could be detected.
- a non-fluorescent compound ⁇ -naphthol- ⁇ -galactopyranoside is cleaved by ⁇ -galactosidase and the liberated naphthol is trapped to form an insoluble fluorescent product.
- the insolubility of the fluorescent product is of great importance here to prevent its diffusion from the cell. Such diffusion would not only lead to an underestimation of ⁇ -galactosidase activity in highly active cells but could also lead to an overestimation of enzyme activity in inactive cells or those with low activity, as they may take up the leaked fluorescent compound, thus reducing the apparent heterogeneity of the population.
- the technique used to monitor b-galactosidase expression from spo-lacZ fusions in single cells involved taking samples from a sporulating culture, staining them with a commercially available fluorogenic substrate for b-galactosidase called C8-FDG, and quantitatively analyzing fluorescence in single cells by flow cytometry.
- the flow cytometer was used as a detector to screen for the presence of the spo gene during the development of the cells.
- the device was not used to screen and recover positive cells from a gene expression library or nucleic acid for the purpose of discovery.
- Another group has utilized flow cytometry to distinguish between the developmental stages of the delta-proteobacteria Myxococcus xanthus (F. Russo-Marie, et. al., PNAS, Vol. 90, pp. 8194-8198, September 1993).
- this study employed the capabilities of the FACS machine to detect and distinguish genotypically identical cells in different development regulatory states. The screening of an enzymatic activity was used in this study as an indirect measure of developmental changes.
- the lacZ gene from E. coli is often used as a reporter gene in studies of gene expression regulation, such as those to determine promoter efficiency, the effects of trans-acting factors, and the effects of other regulatory elements in bacterial, yeast, and animal cells.
- a chromogenic substrate such as ONPG (o-nitrophenyl-(-D-galactopyranoside)
- ONPG o-nitrophenyl-(-D-galactopyranoside
- fluorogenic substrates makes it possible to determine ⁇ -galactosidase activity in a large number of individual cells by means of flow cytometry.
- gel microdroplets containing (physically) single cells which can take up nutrients, secret products, and grow to form colonies.
- the diffusional properties of gel microdroplets may be made such that sufficient extracellular product remains associated with each individual gel microdroplet, so as to permit flow cytometric analysis and cell sorting on the basis of concentration of secreted molecule within each microdroplet.
- Beads have also been used to isolate mutants growing at different rates, and to analyze antibody secretion by hybridoma cells and the nutrient sensitivity of hybridoma cells.
- the gel microdroplet method has also been applied to the rapid analysis of mycobacterial growth and its inhibition by antibiotics.
- the gel microdroplet technology has had significance in amplifying the signals available in flow cytometric analysis, and in permitting the screening of microbial strains in strain improvement programs for biotechnology.
- Wittrup et. al. (Biotechnolo. Bioeng. (1993) 42:351-356) developed a microencapsulation selection method which allows the rapid and quantitative screening of >10 6 yeast cells for enhanced secretion of Aspergillus awamori glucoamylase. The method provides a 400-fold single-pass enrichment for high-secretion mutants.
- Gel microdroplet or other related technologies can be used in the present invention to localize as well as amplify signals in the high throughput screening of recombinant libraries. Cell viability during the screening is not an issue or concern since nucleic acid can be recovered from the microdroplet.
- encapsulation strategies and compounds or polymers can be used with the present invention.
- high temperature agaroses can be employed for making microdroplets stable at high temperatures, allowing stable encapsulation of cells subsequent to heat kill steps utilized to remove all background activities when screening for thermostable bioactivities.
- the present invention adapts traditional eukaryotic flow cytometry cell sorting systems to high throughput screening for expression clones in prokaryotes.
- expression libraries derived from DNA primarily DNA directly isolated from the environment, are screened very rapidly for bioactivities of interest utilizing fluorescense activated cell sorting.
- These libraries can contain greater than 10 8 members and can represent single organisms or can represent the genomes of over 100 different microorganisms, species or subspecies.
- This invention differs from fluorescense activated cell sorting, as normally performed, in several aspects.
- FACS machines have been employed in the studies focused on the analyses of eukaryotic and prokaryotic cell lines and cell culture processes.
- FACS has also been utilized to monitor production of foreign proteins in both eukaryotes and prokaryotes to study, for example, differential gene expression, etc.
- the detection and counting capabilities of the FACS system have been applied in these examples.
- FACS has never previously been employed in a discovery process to screen for and recover bioactivities in prokaryotes.
- the present invention does not require cells to survive, as do previously described technologies, since the desired nucleic acid (recombinant clones) can be obtained from alive or dead cells.
- the cells only need to be viable long enough to produce the compound to be detected, and can thereafter be either viable or non-viable cells so long as the expressed biomolecule remains active.
- the present invention also solves problems that would have been associated with detection and sorting of E. coli expressing recombinant enzymes, and recovering encoding nucleic acids. Additionally, the present invention includes within its embodiments any apparatus capable of detecting flourescent wavelengths associated with biological material, such apparatii are defined herein as fluorescent analyzers (one example of which is a FACS).
- the present invention allows the rapid screening of complex environmental expression libraries, containing, for example, thousands of different organisms.
- the analysis of a complex sample of this size requires one to screen several million clones to cover this genomic biodiversity.
- the invention represents an extremely high-throughput screening method which allows one to assess this enormous number of clones.
- the method disclosed allows the screening of at least about 36 million clones per hour for a desired biological activity. This allows the thorough screening of environmental libraries for clones expressing novel biomolecules.
- gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest.
- Expression gene libraries are generated, clones are either exposed to the substrate or substrate(s) of interest, hybridized to a probe of interest, or bound to a detectable ligand and positive clones are identified and isolated via fluorescence activated cell sorting.
- Cells can be viable or non-viable during the process or at the end of the process, as nucleic acid encoding a positive activity can be isolated and cloned utilizing techniques well known in the art.
- the present invention provides a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nucleic acid directly isolated from the environment; and (ii) screening said libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify said clones.
- a high throughput cell analyzer preferably a fluorescence activated cell sorter
- the invention provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries made to contain nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify clones which react with the substrate or substrates.
- a high throughput cell analyzer preferably a fluorescence activated cell sorter
- the invention also provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; and (ii) screening said exposed libraries utilizing an assay requiring a binding event or the covalent modification of a target, and a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify positive clones.
- a high throughput cell analyzer preferably a fluorescence activated cell sorter
- FIG. 1 illustrates the substrate spectrum fingerprints and optimum reaction temperatures of five of novel esterases showing the diversity in these enzymes.
- EST# indicates the different enzyme; the temperatures indicate the optimal growth temperatures for the organisms from which the esterases were isolated; “E” indicates the relative activity of each esterase enzyme on each of the given substrates indicated (Hepanoate being the reference).
- FIG. 2 illustrates the cloning of DNA fragments prepared by random cleavage of target DNA to generate a representative library as described in Example 1.
- FIG. 3 In order to assess the total number of clones to be tested (e.g. the number of genome equivalents) a statistical analysis was performed. Assuming that mechanical shearing and gradient purification results in normal distribution of DNA fragment sizes with a mean of 4.5 kbp and variance of 1 kbp, the fraction represented of all possible 1 kbp sequences in a 1.8 Mbp genome is plotted in FIG. 3 as a function of increasing genome equivalents.
- FIG. 4 illustrates the protocol used in the cell sorting method of the invention to screen for recombinant enzymes, in this case using a (library excised into E. coli .
- the expression clones of interest are isolated by sorting. The procedure is described in detail in Examples 1, 3 and 4.
- FIG. 5 shows ⁇ -galactosidase clones stained with three different substrates: fluorescein-di- ⁇ -D-galactopyranoside (FDG), C12-fluorescein-di- ⁇ -D-galactopyranoside (C12FDG), chloromethyl-fluorescein-di- ⁇ -D-galactopyranoside (CMFDG).
- FDG fluorescein-di- ⁇ -D-galactopyranoside
- C12FDG C12-fluorescein-di- ⁇ -D-galactopyranoside
- CMFDG chloromethyl-fluorescein-di- ⁇ -D-galactopyranoside
- FIG. 6 shows a microtiter plate where E. coli cells sorted in accordance with the invention are dispensed, one cell per well and grown up as clones which are then stained with fluorescein-di- ⁇ -D-galactopyranoside (FDG) (10 mM). This illustrates the results of the experiments described in Example 5.
- FDG fluorescein-di- ⁇ -D-galactopyranoside
- FIG. 7 shows the principle type of fluorescence enzyme assay of deacylation.
- FIG. 8 shows staining of ⁇ -galactosidase clones from the hyperthermophilic archaeon Sulfolobus solfataricus expressed in E. coli using C 12 -FDG as enzyme substrate.
- FIG. 9 shows the synthesis of 5-dodecanoyl-aminofluorescein-di-dodecanoic acid.
- FIG. 10 shows Rhodamine protease substrate.
- FIG. 11 shows a compound and process that can be used in the detection of monooxygenases.
- FIG. 12 is a schematic illustration of combinatorial enzyme development using directed evolution.
- FIG. 13 is a schematic illustration showing bypassing barriers to directed evolution.
- the method of the present invention begins with the construction of gene libraries which represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts.
- the microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. Libraries may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism. Such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, alkalophiles, acidophiles, etc.
- prokaryotic microorganisms such as Eubacteria and Archaebacteria
- lower eukaryotic microorganisms such as fungi, some algae and protozoa.
- Libraries may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.
- Such microorganisms may be extremophile
- Sources of microorganism DNA as a starting material library from which target DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
- genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme or other biological activity.
- Prokaryotic expression libraries created from such starting material which includes DNA from more than one species are defined herein as multispecific libraries.
- viable or non-viable cells isolated from the environment are, prior to the isolation of nucleic acid for generation of the expression gene library, FACS sorted to separate prokaryotic cells from the sample based on, for instance, DNA or AT/GC content of the cells.
- FACS sorted to separate prokaryotic cells from the sample based on, for instance, DNA or AT/GC content of the cells.
- Various dyes or stains well known in the art for example those described in “Practical Flow Cytometry”, 1995 Wiley-Liss, Inc., Howard M. Shapiro, M.D., are used to intercalate or associate with nucleic acid of cells, and cells are separated on the FACS based on relative DNA content or AT/GC DNA content in the cells.
- Other criteria can also be used to separate prokaryotic cells from the sample, as well.
- DNA is then isolated from the cells and used for the generation of expression gene libraries, which are then screened using the FACS for activities of interest.
- the nucleic acid is isolated directly from the environment and is, prior to generation of the gene library, sorted based on DNA or AT/GC content.
- DNA isolated directly from the environment is used intact, randomly sheared or digested to general fragmented DNA.
- the DNA is then bound to an intercalating agent as described above, and separated on the analyzer based on relative base content to isolate DNA of interest. Sorted DNA is then used for the generation of gene libraries, which are then screened using the analyzer for activities of interest.
- the present invention can further optimize methods for isolation of activities of interest from a variety of sources, including consortias of microorganisms, primary enrichments, and environmental “uncultivated” samples, to make libraries which have been “normalized” in their representation of the genome populations in the original samples. and to screen these libraries for enzyme and other bioactivities. Libraries with equivalent representation of genomes from microbes that can differ vastly in abundance in natural populations are generated and screened. This “normalization” approach reduces the redundancy of clones from abundant species and increases the representation of clones from rare species. These normalized libraries allow for greater screening efficiency resulting in the identification of cells encoding novel biological catalysts.
- One embodiment for forming a normalized library from an environmental sample begins with the isolation of nucleic acid from the sample. This nucleic acid can then be fractionated prior to normalization to increase the chances of cloning DNA from minor species from the pool of organisms sampled. DNA can be fractionated using a density centrifugation technique, such as a cesium-chloride gradient. When an intercalating agent, such as bis-benzimide is employed to change the buoyant density of the nucleic acid, gradients will fractionate the DNA based on relative base content. Nucleic acid from multiple organisms can be separated in this manner, and this technique can be used to fractionate complex mixtures of genomes. This can be of particular value when working with complex environmental samples.
- a density centrifugation technique such as a cesium-chloride gradient.
- an intercalating agent such as bis-benzimide
- the DNA does not have to be fractionated prior to normalization.
- Samples are recovered from the fractionated DNA, and the strands of nucleic acid are then melted and allowed to selectively reanneal under fixed conditions (C o t driven hybridization).
- C o t driven hybridization When a mixture of nucleic acid fragments is melted and allowed to reanneal under stringent conditions, the common sequences find their complementary strands faster than the rare sequences.
- single-stranded nucleic acid representing an enrichment of rare sequences is amplified using techniques well known in the art, such as a polymerase chain reaction (Barnes, 1994), and used to generate gene libraries.
- This procedure leads to the amplification of rare or low abundance nucleic acid molecules, which are then used to generate a gene library which can be screened for a desired bioactivity. While DNA will be recovered, the identification of the organism(s) originally containing the DNA may be lost. This method offers the ability to recover DNA from “unclonable” sources.
- one embodiment for forming a normalized library from environmental sample(s) is by (a) isolating nucleic acid from the environmental sample(s); (b) optionally fractionating the nucleic acid and recovering desired fractions; (c) normalizing the representation of the DNA within the population so as to form a normalized expression library from the DNA of the environmental sample(s).
- the “normalization” process is described and exemplified in detail in co-pending, commonly assigned U.S. Ser. No. 08/665,565, filed Jun. 18, 1996.
- DNA from the sample is an important step in the generation of normalized or non-normalized DNA libraries from environmental samples composed of uncultivated organisms, or for the generation of libraries from cultivated organisms.
- DNA can be isolated from samples using various techniques well known in the art (Nucleic Acids in the Environment Methods & Applications, J. T. Trevors, D. D. van Elsas, Springer Laboratory, 1995).
- DNA obtained will be of large size and free of enzyme inhibitors or other contaminants.
- DNA can be isolated directly from an environmental sample (direct lysis), or cells may be harvested from the sample prior to DNA recovery (cell separation) . Direct lysis procedures have several advantages over protocols based on cell separation.
- the direct lysis technique provides more DNA with a generally higher representation of the microbial community, however, it is sometimes smaller in size and more likely to contain enzyme inhibitors than DNA recovered using the cell separation technique.
- Very useful direct lysis techniques have been described which provide DNA of high molecular weight and high purity (Barns, 1994; Holben, 1994). If inhibitors are present, there are several protocols which utilize cell isolation which can be employed (Holben, 1994). Additionally, a fractionation technique, such as the bis-benzimide separation (cesium chloride isolation) described, can be used to enhance the purity of the DNA.
- CTL total genomic DNA from extreme environmental samples varies depending on the source and quantity of material. Uncontaminated, good quality (>20 kbp) DNA is required for the construction of a representative library.
- a successful general DNA isolation protocol is the standard cetyl-trimethyl-ammonium-bromide (CTAB) precipitation technique.
- CTCAB cetyl-trimethyl-ammonium-bromide
- a biomass pellet is lysed and proteins digested by the nonspecific protease, proteinase K, in the presence of the detergent SDS.
- CTAB forms insoluble complexes with denatured protein, polysaccharides and cell debris. Chloroform extractions are performed until the white interface containing the CTAB complexes is reduced substantially.
- the nucleic acids in the supernatant are precipitated with isopropanol and resuspended in TE buffer.
- Gene libraries can be generated by inserting the DNA isolated or derived from a sample into a vector or a plasmid.
- vectors or plasmids are preferably those containing expression regulatory sequences, including promoters, enhancers and the like.
- polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmids and methods for introduction and packaging into them are described herein.
- Shear DNA (for example, with a 25 gauge needle)
- cloning DNA fragments prepared by random cleavage of the target DNA generates a representative library.
- DNA dissolved in TE buffer is vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments are in the desired size range.
- the DNA ends are “polished” or blunted with Mung Bean Nuclease, and EcoRI restriction sites in the target DNA are protected with EcoRI Methylase.
- EcoRI linkers GGAATTCC
- the linkers are cut back with EcoRI restriction endonuclease and the DNA is size fractionated.
- the removal of sub-optimal DNA fragments and the small linkers is critical because ligation to the vector will result in recombinant molecules that are unpackageable, or the construction of a library containing only linkers as inserts.
- Sucrose gradient fractionation is used since it is extremely easy, rapid and reliable. Although the sucrose gradients do not provide the resolution of agarose gel isolations, they do produce DNA that is relatively free of inhibiting contaminants.
- the prepared target DNA is ligated to the lambda vector, packaged using in vitro packaging extracts and grown on the appropriate E. coli.
- expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.)
- the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide.
- Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences.
- suitable vectors are known to those of skill in the art, and are commercially available.
- the following vectors are provided by way of example; Bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, PBPV, PMSG, pSVLSV40 (Pharmacia).
- any other plasmid or other vector may be used as long as they are replicable and viable in the host.
- Another type of vector for use in the present invention contains an f-factor origin replication.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis.
- promoter particularly named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P R , P L and trp.
- Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
- promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), (-factor, acid phosphatase, or heat shock proteins, among others.
- PGK 3-phosphoglycerate kinase
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the cloning strategy permits expression via both vector driven and endogenous promoters; vector promotion may be important with expression of genes whose endogenous promoter will not function in E. coli.
- the DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity.
- the selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity.
- the host cell is a prokaryotic cell, such as a bacterial cell. Particularly preferred host cells are E. coli .
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
- the selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- expression libraries generated can be phage display or cell surface display libraries. Numerous techniques are published in the art for generating such libraries.
- biopanning such libraries prior to screening by cell sorting.
- the “biopanning” procedure refers to a process for identifying clones having a specified biological activity by screening for sequence homology in a library of clones prepared by (i) selectively isolating target DNA, from DNA derived from at least one microorganism, by use of at least one probe DNA comprising at least a portion of a DNA sequence encoding an biological having the specified biological activity; and (ii) transforming a host with isolated target DNA to produce a library of clones which are screened for the specified biological activity.
- the probe DNA used for selectively isolating the target DNA of interest from the DNA derived from at least one microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity.
- the original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding an enzyme having the specified enzyme activity.
- These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form.
- the probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.
- the probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which target DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate target DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source.
- the ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor.
- the solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- the target DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts.
- the double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- the selected DNA is then used for preparing a library for screening by transforming a suitable organism.
- Hosts particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- the screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened utilizing a FACS machine for such enzyme activity or for a more specific activity. Alternatively, encapsulation techniques such as gel microdroplets, may be employed to localize multiple clones in one location to be screened on a FACS machine for positive expressing clones within the group of clones which can then be broken out into individual clones to be screened again on a FACS machine to identify positive individual clones. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened utilizing a FACS machine to determine which of such clones has hydrolase activity.
- the invention provides a process for enzyme activity screening of clones containing selected DNA derived from a microorganism which process comprises:
- screening a library for specified enzyme activity said library including a plurality of clones, said clones having been prepared by recovering from genomic DNA of a microorganism selected DNA, which DNA is selected by hybridization to at least one DNA sequence which is all or a portion of a DNA sequence encoding an enzyme having the specified activity;
- a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by:
- the process includes a preselection to recover DNA including signal or secretion sequences.
- DNA including signal or secretion sequences.
- the process includes a preselection to recover DNA including signal or secretion sequences.
- the following paragraphs describe the protocol for this embodiment of the invention, the nature and function of secretion signal sequences in general and a specific exemplary application of such sequences to an assay or selection process.
- a particularly preferred embodiment of this aspect further comprises, after (a) but before (b) above, the steps of:
- DNA which has been selected and isolated to include a signal sequence is then subjected to the selection procedure hereinabove described to select and isolate therefrom DNA which binds to one or more probe DNA sequences derived from DNA encoding an enzyme(s) having the specified enzyme activity.
- In-vivo biopanning may be performed utilizing a FACS-based machine.
- Complex gene libraries are constructed with vectors which contain elements which stabilize transcribed RNA. For example, the inclusion of sequences which result in secondary structures such as hairpins which are designed to flank the transcribed regions of the RNA would serve to enhance their stability, thus increasing their half life within the cell.
- the probe molecules used in the biopanning process consist of oligonucleotides labeled with reporter molecules that only fluoresce upon binding of the probe to a target molecule (e.g. molecular beacons—see ref.). These probes are introduced into the recombinant cells from the library using one of several transformation methods. The probe molecules bind to the transcribed target mRNA resulting in DNA/RNA heteroduplex molecules. Binding of the probe to a target will yield a fluorescent signal which is detected and sorted by the FACS machine during the screening process.
- a normalization step is performed prior to generation of the expression library, the expression library is then generated, the expression library so generated is then biopanned, and the biopanned expression library is then screened using a high throughput cell sorting and screening instrument.
- a normalization step is performed prior to generation of the expression library, the expression library is then generated, the expression library so generated is then biopanned, and the biopanned expression library is then screened using a high throughput cell sorting and screening instrument.
- the library may, for example, be screened for a specified enzyme activity.
- the enzyme activity screened for may be one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases.
- the recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- the library may be screened for a more specialized enzyme activity.
- the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts.
- the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- the clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the DNA sequence encoding an enzyme having the specified activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the present invention may be employed for example, to identify new enzymes having, for example, the following activities which may be employed for the following uses:
- the present invention also offers the ability to screen for other types of bioactivities. For instance, the ability to select and combine desired components from a library of polyketides and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing.
- the method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide synthases, since one can generate gene banks with clones containing large inserts (especially when using vectors which can accept large inserts, such as the f-factor based vectors), which facilitates cloning of gene clusters.
- the gene cluster or pathway DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli .
- this f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- Other examples of vectors include cosmids, bacterial artificial chromosome vectors, and P1 vectors.
- Lambda vectors can also accommodate relatively large DNA molecules, have high cloning and packaging efficiencies and are easy to handle and store compared to plasmid vectors.
- -ZAP vectors Stratagene Cloning Systems, Inc.
- the cloning site in these vectors lies downstream of the lac promoter. This feature allows expression of genes whose endogenous promoter does not function in E. coli.
- the two main factors which govern the total number of clones that can be pooled and simultaneously screened are (i) the level of gene expression and (ii) enzyme assay sensitivity.
- As estimate of the level of gene expression is that each E. coli cell infected with lambda will produce 10 3 copies of the gene product from the insert.
- FACS instruments are sufficiently sensitive to detect about 500 to 1000 Fluorescein molecules.
- Substrate can be administered to the cells before or during the process of the cell sorting analysis. In either case a solution of the substrate is made up and the cells are contacted therewith. When done prior to the cell sorting analysis this can be by making a solution which can be administered to the cells while in culture plates or other containers.
- concentration ranges for substrate solutions will vary according to the substrate utilized. Commercially available substrates will generally contain instructions on concentration ranges to be utilized for, for instance, cell staining purposes. These ranges may be employed in the determination of an optimal concentration or concentration range to be utilized in the present invention.
- the substrate solution is maintained in contact with the cells for a period of time and at an appropriate temperature necessary for the substrate to permeablize the cell membrane. Again, this will vary with substrate.
- Instruments which deliver reagents in stream such as by poppet valves which seal openings in the flow path until activated to permit introduction of reagents (e.g. substrate) into the flow path in which the cells are moving through the analyzer can be employed for substrate delivery.
- reagents e.g. substrate
- the substrate is one which is able to enter the cell and maintain its presence within the cell for a period sufficient for analysis to occur. It has generally been observed that introduction of the substrate into the cell across the cell membrane occurs without difficulty. It is also preferable that once the substrate is in the cell it not “leak” back out before reacting with the biomolecule being sought to an extent sufficient to product a detectable response. Retention of the substrate in the cell can be enhanced by a variety of techniques.
- the substrate compound is structurally modified by addition of a hydrophobic tail.
- certain preferred solvents such as DMSO or glycerol, can be administered to coat the exterior of the cell. Also the substrate can be administered to the cells at reduced temperature which has been observed to retard leakage of the substrate from the cell's interior.
- a broad spectrum of substrates can be used which are chosen based on the type of bioactivity sought.
- the bioactivity can be examined using a cocktail of the known substrates for the related biomolecules which are already known.
- substrates are known for approximately 20 commercially available esterases and the combination of these known substrates can provide detectable, if not optimal, signal production.
- Substrates are also known and available for glycosidases, proteases, phosphatases, and monoxygenases.
- the substrate interacts with the target biomolecule so as to produce a detectable response.
- Such responses can include chromogenic or fluorogenic responses and the like.
- the detectable species can be one which results from cleavage of the substrate or a secondary molecule which is so affected by the cleavage or other substrate/biomolecule interaction to undergo a detectable change.
- Innumerable examples of detectable assay formats are known from the diagnostic arts which use immunoassay, chromogenic assay, and labeled probe methodologies.
- FIG. 7 shows the basic principle for this type of enzyme assay for deacylation. Any emission or activation of fluorescent wavelengths as a result of any biological process are defined herein as bioactive fluoresence.
- reporter genes encode enzymes not ordinarily found in the type of cell being studied, and their unique activity is monitored to determine the degree of transcription.
- Nolan et al. developed a technique to analyze (-galactosidase expression in mammalian cells employing fluorescein-di-(-D-galactopyranoside (FDG) as a substrate for (-galactosidase, which releases fluorescein, a product that can be detected by a fluorescence-activated cell sorter (FACS) upon hydrolysis (Nolan et al., 1991).
- FDG fluorescein-di-(-D-galactopyranoside
- FACS fluorescence-activated cell sorter
- FDG fluorescence leaks out of the positively stained cells.
- a similar problem was encountered in other studies of (-galactosidase measurements in mammalian cells and yeast with FDG as well as other substrates (Nolan et al, 1988; Wittrup et al., 1988). Performing the reaction at 0° C. appreciably decreased the extent of this leakage of fluorescence (Nolan et al., 1988). However this low temperature is not adaptable for screening for, for instance, high temperature (-galactosidases.
- C 12 -FDG 5-dodecanoylamino fluorescein di-(-D-galactopyranoside
- Molecular Probes which differs from FDG in that it is a lipophilic fluorescein derivative that can easily cross most cell membranes under physiological culture conditions.
- the green fluorescent enzymatic hydrolysis product is retained for hours to days in the membrane of those cells that actively express the lacZ reporter gene.
- C 12 -FDG was a much better substrate, giving a signal which was 100 times higher than the one obtained with FDG (Plovins et al., 1994).
- Gram negative bacteria like E like E.
- the outer membrane functions as a barrier for the lipophilic molecule C 12 -FDG and it only passes through this barrier if the cells are dead or damaged (Plovins et al).
- C 12 retains FDG substrate inside the cells indicates that the addition of unpolarized tails may be used for retaining substrate inside the cells with respect to other enzyme substrates.
- the abovementioned (-galactosidase assays may be employed to screen single E. coli cells, expressing recombinant (-D-galactosidase isolated from a hyperthermophilic archaeon such as Sulfolobus solfataricus , on a fluorescent microscope. Cells are cultivated overnight, centrifuged and washed in deionized water and stained with FDG. To increase enzyme activity, cells are heated to 70° C. for 30 minutes and examined with a fluorescence phase contrast microscope. E. coli cell suspensions of the (-galactosidase expressing clone stained with C 12 -FDG show a very bright fluorescence inside single cells (FIG. 8).
- DMSO can be used as solvent up to a concentration of 50% in water to dissolve and load substrates without significantly dropping the viability of E. coli . Enzyme activity and leakage can be monitored with fluorescence microscopy.
- An acylated derivative of fluorescein can be used to detect esterases such as lipases.
- the fluorophore is hydrolyzed from the derivative to generate a signal.
- Acylated derivatives of fluorescein can be synthesized according to FIG. 9.
- Nine molar equivalents of lauric anhydride triethylamine and N,N-diisopropylethylamine are added to a solution of fluoresceinamine in chloroform. After the reaction is complete, the product 5-dodecanoyl-aminofluorescein-di-dodecanoic acid (C 12 -FDC 12 ) is recrystallized.
- Proteases can be assayed in the same way as the esterases, with an amide being cleaved instead of an ester.
- Rhodamine derivatives (FIG. 10), have more lipophilic characteristics compared to fluorescein protrease substrates, therefore they make good substrates for more general assays.
- a variety of types of high throughput cell sorting instruments can be used with the present invention.
- Other types of instruments which can be used are robotics instruments and time-resolved fluorescence instruments, which can actually measure the fluorescence from a single molecule over an elapsed period of time. Since they are measuring a single molecule, they can simultaneously determine its molecular weight, however their throughput is not as high as the FACS cell sorting instruments.
- the trigger parameter is set with logarithmic forward side scatter.
- the fluorescent signals of positive clones emitted by fluorescein or other fluorescent substrates is distinguished by means of a dichroic mirror and acquired in log mode.
- “active” clones can be sorted and deposited into microtiter plates.
- approximately 50 clones can be sorted into individual microtiter plate wells.
- complex environmental mega-libaries i.e. libraries containing ⁇ 10 8 clones which represent >100 organisms
- about 500 expressing clones should be collected.
- Plasmid DNA can then be isolated from the sorted clones using any commercially available automated miniprep machine, such as that from Autogen.
- the plasmids are then retransformed into suitable expression hosts and assayed for activity utilizing chromogenic agar plate based or automated liquid format assays.
- Confirmed expression clones can then undergo RFLP analysis to determine unique clones prior to sequencing.
- the inserts which contain the unique esterase clones can be sequenced, open reading frames (ORF's) identified and the genes PCR subcloned for overexpression.
- ORF's open reading frames
- expressing clones can be “bulk sorted” into single tubes and the plasmid inserts recovered as amplified products, which are then subcloned and transformed into suitable vector-hosts systems for rescreening.
- Encapsulation techniques may be employed to localize signal, even in cases where cells are no longer viable.
- Gel microdrops are small (25 to Sum in diameter) particles made with a biocompatible matrix. In cases of viable cells, these microdrops serve as miniaturized petri dishes because cell progeny are retained next to each other, allowing isolation of cells based on clonal growth.
- the basic method has a significant degree of automation and high throughput; after the colony size signal boundaries are established, about 10 6 GMDs per hour can be automatically processed.
- Cells are encapsulated together with substrates and particles containing a positive clones are sorted. Fluorescent substrate labeled glass beads can also be loaded inside the GMDs. In cases of non-viable cells, GMDs can be employed to ensure localization of signal.
- each containing a different expression clone from the gene library are screened on a FACS machine, and positive clones are recovered, DNA is isolated from positive clones.
- the DNA can then be amplified either in vivo or in vitro by utilizing any of the various amplification techniques known in the art. In vivo amplification would include transformation of the clone(s) or subclone(s) of the clones into a viable host, followed by growth of the host. In vitro amplification can be performed using techniques such as the polymerase chain reaction.
- Clones found to have the bioactivity for which the screen was performed can also be subjected to directed mutagenesis to develop new bioactivities with desired properties or to develop modified bioactivities with particularly desired properties that are absent or less pronounced in the wild-type enzyme, such as stability to heat or organic solvents.
- Any of the known techniques for directed mutagenesis are applicable to the invention.
- particularly preferred mutagenesis techniques for use in accordance with the invention include those described below.
- error-prone PCR refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Leung, D. W., et al., Technique, 1:11-15 (1989) and Caldwell, R. C. & Joyce G. F., PCR Methods Applic., 2:28-33 (1992).
- oligonucleotide directed mutagenesis refers to a process which allows for the generation of site-specific mutations in any cloned DNA segment of interest. Reidhaar-Olson, J. F. & Sauer, R. T., et al., Science, 241:53-57 (1988).
- assembly PCR refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.
- the term “sexual PCR mutagenesis” (also known as “DNA shuffling”) refers to forced homologous recombination between DNA molecules of different but highly related DNA sequence in vitro, caused by random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Stemmer, W. P., PNAS, USA, 91:10747-10751 (1994).
- in vivo mutagenesis refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of E. coli that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propogating the DNA in one of these strains will eventually generate random mutations within the DNA.
- cassette mutagenesis refers to any process for replacing a small region of a double stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence.
- the oligonucleotide often contains completely and/or partially randomized native sequence.
- recursive ensemble mutagenesis refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Arkin, A. P. and Youvan, D. C., PNAS, USA, 89:7811-7815 (1992).
- exponential ensemble mutagenesis refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins, Delegrave, S. and Youvan, D. C., Biotechnology Research, 11:1548-1552 (1993); and random and site-directed mutagenesis, Arnold, F. H., Current Opinion in Biotechnology, 4:450-455 (1993).
- DNA can be mutagenized, or “evolved”, utilizing any one or more of these techniques, and rescreened on the FACS machine to identify more desirable clones.
- Internal control reference genes which either express fluorescing molecules, such as those encoding green fluorescent protein, or encode proteins that can turnover fluorescing molecules, such as beta-galactosidase, can be utilized. These internal controls should optimally fluoresce at a wavelength which is different from the wavelength at which the molecule used to detect the evolved molecule(s) emits.
- DNA is evolved, recloned in a vector which co-expresses these proteins or molecules, transformed into an appropriate host organism, and rescreened utilizing the FACS machine to identify more desirable clones.
- An important aspect of the invention is that cells are being analyzed individually. However other embodiments are contemplated which involve pooling of cells and multiple passage screen. This provides for a tiered analysis of biological activity from more general categories of activity, i.e. categories of enzymes, to specific activities of principle interest such as enzymes of that category which are specific to particular substrate molecules.
- FACS instruments can detect molecules that fluoresce at different wavelengths, hence substrates which fluoresce at different wavelengths and indicate different activities can be employed.
- the fluorescence activated cell sorting screening method of the present invention allows one to assay several million clones per hour for a desired bioactivity. This technique provides an extremely high throughput screening process necessary for the screening of extreme biodiverse environmental libraries.
- DNA can be normalized according to Example 2.
- pool fractions 1-4 (about 10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb).
- DNA is first fractionated according to the following protocol:
- Sample composed of genomic DNA is purified on a cesium-chloride gradient.
- the DNA is added and thoroughly mixed.
- Ten micrograms of bis-benzimide (Sigma; Hoechst 33258) is added and mixed thoroughly.
- the tube is then filled with the filtered cesium chloride solution and spun in a VTi50 rotor in a Beckman L8-70 Ultracentrifuge at 33,000 rpm for 72 hours.
- a syringe pump and fractionator (Brandel Model 186) are used to drive the gradient through an ISCO UA-5 UV absorbance detector set to 280 nm. Peaks representing the DNA from the organisms present in an environmental sample are obtained. Eubacterial sequences can be detected by PCR amplification of DNA encoding rRNA from a 10-fold dilution of the E. coli peak using the following primers to amplify:
- Forward primer Forward primer: 5′-AGAGTTTGATCCTGGCTCAG-3′
- Reverse primer 5′-GGTTACCTTGTTACGACTT-3′
- Recovered DNA is sheared or enzymatically digested to 3-6 kb fragments. Lone-linker primers are ligated and the DNA is sized selected. Size-selected DNA is amplified by PCR, if necessary.
- Double-stranded DNA sample is resuspended in hybridization buffer (0.12 M NaH 2 PO 4 , pH 6.8/0.82 M NaCl/1 mM EDTA/0.1% SDS).
- Sample is overlaid with mineral oil and denatured by boiling for 10 minutes.
- Double-stranded DNA is separated from single-stranded DNA according to standard protocols (Sambrook, 1989) on hydroxyapatite at 60(C.
- the single-stranded DNA fraction is desalted and amplified by PCR.
- Gene libraries including those generated as described in Example 1, can be screened for bioactivities of interest on a FACS machine as indicated herein.
- a screening process begins with staining of the cells with a desirable substrate according to the following example.
- a gene library is made from the hyperthermophilic archaeon Sulfulobus solfataricus in the (-ZAPII vector according to the manufacturers instructions (Stratagene Cloning Systems, Inc., La Jolla, Calif.), and excised into the pBluescript plasmid according to the manufacturers instructions (Stratagene) . DNA was isolated using the IsoQuick DNA isolation kit according to the manufacturers instructions (Orca, Inc., Bothell, Wash.).
- Cells are resuspended in 1 ml of deionized water, and stained with C 12 -Fluoroscein-Di-(-D-galactopyranoside (FDG) as follows: 0.5 ml Cells 50 (l C 12 -FDG staining solution (1 mg C 12 -FDG in 1 ml of a mixture of 98% H2O, 1% DMSO, 1% EtOH) 50 (l Propidium iodide (PI) staining solution (50 (g/ml of distilled water)
- FDG C 12 -Fluoroscein-Di-(-D-galactopyranoside
- Sample is incubated in the dark at 37(C with shaking at 150 rpm for 30 minutes.
- the excised (-ZAP II library is incubated for 2 hours and induced with IPTG.
- Cells are centrifuged, washed and stained with the desired enzyme substrate, for example C 12 -Fluoroscein-Di-(-D-galactopyranoside (FDG) as in Example 3.
- FDG C 12 -Fluoroscein-Di-(-D-galactopyranoside
- Clones are sorted on a commercially available FACS machine, and positives are collected.
- Cells are lysed according to standard techniques (Current Protocols in Molecular Biology, 1987) and plasmids are transformed into new host by electroporation using standard techniques. Transformed cells are plated for secondary screening. The procedure is illustrated in FIG. 5.
- Sorted organisms can be grown and plated for secondary screening.
- Cells can be sorted in a FACS instrument directly on microtiter plates in accordance with the present invention. Sorting in this fashion facilitates downstream processing of positive clones.
- E. coli cells containing (-galactosidase genes are exposed to a staining solution in accordance with Example 3. These cells are then left to sit on ice for three minutes. For the cell sorting procedure they are diluted 1:100 in deionized water or in Phospate Buffered Saline buffer solution according to the manufacturers protocols for cell sorting. The cells are then sorted by the FACS instrument into microtiter plates, one cell per well. The sorting criteria is fluorescein fluorescence indicating (-galactosidase activity or PI for indicating the staining of dead cells (unlike viable cells, dead cells have no membrane potential; hence PI remains in the cell with dead cells and is pumped out with live cells) . Results as observed on the microtiter plate are shown in FIG. 6.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed is a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nuclei acid directly isolated from the environment; and (ii) screening said libraries utilizing a fluorescence activated cell sorter to identify said clones. More particularly, this is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a fluorescence activated cell sorter to identify clones which react with the substrate or substrates. Also provided is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; and (ii) screening said exposed libraries utilizing an assay requiring a binding event or the covalent modification of a target, and a fluorescence activated cell sorter to identify positive clones.
Description
- The present invention relates to the discovery of new bioactive molecules, such as biocatalysts. This invention employs high throughput cell analyzing, in particular fluorescence activated cell sorting (FACS), machines in a screening system designed for the rapid discovery of a large number of these molecules.
- There is a critical need in the chemical industry for efficient catalysts for the practical synthesis of optically pure materials; enzymes can provide the optimal solution. All classes of molecules and compounds that are utilized in both established and emerging chemical, pharmaceutical, textile, food and feed, detergent markets must meet stringent economical and environmental standards. The synthesis of polymers, pharmaceuticals, natural products and agrochemicals is often hampered by expensive processes which produce harmful byproducts and which suffer from low enantioselectivity (Faber, 1995; U.S. Tonkovich and Gerber, Dept. of Energy study, 1995). Enzymes have a number of remarkable advantages which can overcome these problems in catalysis: they act on single functional groups, they distinguish between similar functional groups on a single molecule, and they distinguish between enantiomers. Moreover, they are biodegradable and function at very low mole fractions in reaction mixtures. Because of their chemo-, regio- and stereospecificity, enzymes present a unique opportunity to optimally achieve desired selective transformations. These are often extremely difficult to duplicate chemically, especially in single-step reactions. The elimination of the need for protection groups, selectivity, the ability to carry out multi-step transformations in a single reaction vessel, along with the concomitant reduction in environmental burden, has led to the increased demand for enzymes in chemical and pharmaceutical industries (Faber, 1995). Enzyme-based processes have been gradually replacing many conventional chemical-based methods (Wrotnowski, 1997). A current limitation to more widespread industrial use is primarily due to the relatively small number of commercially available enzymes. Only ˜300 enzymes (excluding DNA modifying enzymes) are at present commercially available from the >3000 non DNA-modifying enzyme activities thus far described.
- The use of enzymes for technological applications also may require performance under demanding industrial conditions. This includes activities in environments or on substrates for which the currently known arsenal of enzymes was not evolutionarily selected. Enzymes have evolved by selective pressure to perform very specific biological functions within the milieu of a living organism, under conditions of mild temperature, pH and salt concentration. For the most part, the non-DNA modifying enzyme activities thus far described (Enzyme Nomenclature, 1992) have been isolated from mesophilic organisms, which represent a very small fraction of the available phylogenetic diversity (Amann et al., 1995). The dynamic field of biocatalysis takes on a new dimension with the help of enzymes isolated from microorganisms that thrive in extreme environments. Such enzymes must function at temperatures above 100° C. in terrestrial hot springs and deep sea thermal vents, at temperatures below 0° C. in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge (Adams and Kelly, 1995). Enzymes obtained from these extremophilic organisms open a new field in biocatalysis.
- For example, several esterases and lipases cloned and expressed from extremophilic organisms are remarkably robust, showing high activity throughout a wide range of temperatures and pHs. The fingerprints of five of these esterases show a diverse substrate spectrum, in addition to differences in the optimum reaction temperature. As seen in FIG. 1,
esterase # 5 recognizes only short chain substrates while #2 only acts on long chain substrates in addition to a huge difference in the optimal reaction temperature. These results suggest that more diverse enzymes fulfilling the need for new biocatalysts can be found by screening biodiversity. Substrates upon which enzymes act are herein defined as bioactive substrates. - Furthermore, virtually all of the enzymes known so far have come from cultured organisms, mostly bacteria and more recently archaea (Enzyme Nomenclature, 1992). Traditional enzyme discovery programs rely solely on cultured microorganisms for their screening programs and are thus only accessing a small fraction of natural diversity. Several recent studies have estimated that only a small percentage, conservatively less than 1%, of organisms present in the natural environment have been cultured (see Table I, Amann et al., 1995, Barns et. al 1994, Torvsik, 1990). For example, Norman Pace's laboratory recently reported intensive untapped diversity in water and sediment samples from the “Obsidian Pool” in Yellowstone National Park, a spring which has been studied since the early 1960's by microbiologists (Barns, 1994). Amplification and cloning of 16S rRNA encoding sequences revealed mostly unique sequences with little or no representation of the organisms which had previously been cultured from this pool. This suggests substantial diversity of archaea with so far unknown morphological, physiological and biochemical features which may be useful in industrial processes. David Ward's laboratory in Bozmen, Montana has performed similar studies on the cyanobacterial mat of Octopus Spring in Yellowstone Park and came to the same conclusion, namely, tremendous uncultured diversity exists (Bateson et al., 1989). Giovannoni et al. (1990) reported similar results using bacterioplankton collected in the Sargasso Sea while Torsvik et al. (1990) have shown by DNA reassociation kinetics that there is considerable diversity in soil samples. Hence, this vast majority of microorganisms represents an untapped resource for the discovery of novel biocatalysts. In order to access this potential catalytic diversity, recombinant screening approaches are required.
- The discovery of novel bioactive molecules other than enzymes is also afforded by the present invention. For instance, antibiotics, antivirals, antitumor agents and regulatory proteins can be discovered utilizing the present invention.
- Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. The gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes, usually from 2 to 6 genes. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of one or more identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated of adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
- It is important to further research gene clusters and the extent to which the full length of the cluster is necessary for the expression of the proteins resulting therefrom. Gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including enzymes such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities. As indicated, other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and encoded enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins. The method(s) of the present invention facilitate the rapid discovery of these gene clusters in gene expression libraries.
- The present invention combines a culture-independent approach to directly clone genes encoding novel bioactivities from environmental samples with an extremely high throughput screening system designed for the rapid discovery of new biomolecules.
- The strategy begins with the construction of gene libraries which represent the genome(s) of microorganisms archived in cloning vectors that can be propagated in E. coli or other suitable prokaryotic hosts. Preferably, “environmental libraries” which represent the collective genomes of naturally occurring microorganisms are generated. In this case, because the cloned DNA is extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. In addition, “normalization” can be performed on the environmental nucleic acid as one approach to more equally represent the DNA from all of the species present in the original sample. Normalization techniques can dramatically increase the efficiency of discovery from genomes which may represent minor constituents of the environmental sample. Normalization is preferable since at least one study has demonstrated that an organism of interest can be underrepresented by five orders of magnitude compared to the dominant species (Stetter, pers. comm.).
- When attempting to identify genes encoding bioactivities of interest from complex environmental expression libraries, the rate limiting steps in discovery occur at the both DNA cloning level and at the screening level. Screening of complex environmental libraries which contain, for example, 100's of different organisms requires the analysis of several million clones to cover this genomic diversity. An extremely high-throughput screening method has been developed to handle the enormous numbers of clones present in these libraries.
- In traditional flow cytometry, it is common to analyze very large numbers of eukaryotic cells in a short period of time. Newly developed flow cytometers can analyze and sort up to 20,000 cells per second. In a typical flow cytometer, individual particles pass through an illumination zone and appropriate detectors, gated electronically, measure the magnitude of a pulse representing the extent of light scattered. The magnitude of these pulses are sorted electronically into “bins” or “channels,” permitting the display of histograms of the number of cells possessing a certain quantitative property versus the channel number (Davey and Kell, 1996). It was recognized early on that the data accruing from flow cytometric measurements could be analyzed (electronically) rapidly enough that electronic cell-sorting procedures could be used to sort cells with desired properties into separate “buckets,” a procedure usually known as fluorescence-activated cell sorting (Davey and Kell, 1996).
- Fluorescence-activated cell sorting has been primarily used in studies of human and animal cell lines and the control of cell culture processes. Fluorophore labeling of cells and measurement of the fluorescence can give quantitative data about specific target molecules or subcellular components and their distribution in the cell population. Flow cytometry can quantitate virtually any cell-associated property or cell organelle for which there is a fluorescent probe (or natural fluorescence). The parameters which can be measured have previously been of particular interest in animal cell culture.
- Flow cytometry has also been used in cloning and selection of variants from existing cell clones. This selection, however, has required stains that diffuse through cells passively, rapidly and irreversibly, with no toxic effects or other influences on metabolic or physiological processes. Since, typically, flow sorting has been used to study animal cell culture performance, physiological state of cells, and the cell cycle, one goal of cell sorting has been to keep the cells viable during and after sorting.
- There currently are no reports in the literature of screening and discovery of recombinant enzymes in E. coli expression libraries by fluorescence activated cell sorting of single cells. Furthermore there are no reports of recovering DNA encoding bioactivities screened by expression screening in E. coli using a FACS machine. The present invention provides these methods to allow the extremely rapid screening of viable or non-viable cells to recover desirable activities and the nucleic acid encoding those activities.
- A limited number of papers describing various applications of flow cytometry in the field of microbiology and sorting of fluorescence activated microorganisms have, however, been published (Davey and Kell, 1996). Fluorescence and other forms of staining have been employed for microbial discrimination and identification, and in the analysis of the interaction of drugs and antibiotics with microbial cells. Flow cytometry has been used in aquatic biology, where autofluorescence of photosynthetic pigments are used in the identification of algae or DNA stains are used to quantify and count marine populations (Davey and Kell, 1996). Thus, Diaper and Edwards used flow cytometry to detect viable bacteria after staining with a range of fluorogenic esters including fluorescein diacetate (FDA) derivatives and CemChrome B, a proprietary stain sold commercially for the detection of viable bacteria in suspension (Diaper and Edwards, 1994). Labeled antibodies and oligonucleotide probes have also been used for these purposes.
- Papers have also been published describing the application of flow cytometry to the detection of native and recombinant enzymatic activities in eukaryotes. Betz et al. studied native (non-recombinant) lipase production by the eukaryote, Rhizopus arrhizus with flow cytometry. They found that spore suspensions of the mold were heterogeneous as judged by light-scattering data obtained with excitation at 633 nm, and they sorted clones of the subpopulations into the wells of microtiter plates. After germination and growth, lipase production was automatically assayed (turbidimetrically) in the microtiter plates, and a representative set of the most active were reisolated, cultured, and assayed conventionally (Betz et al., 1984).
- Scrienc et al. have reported a flow cytometric method for detecting cloned -galactosidase activity in the eukaryotic organism, S. cerevisiae. The ability of flow cytometry to make measurements on single cells means that individual cells with high levels of expression (e.g., due to gene amplification or higher plasmid copy number) could be detected. In the method reported, a non-fluorescent compound β-naphthol-β-galactopyranoside) is cleaved by β-galactosidase and the liberated naphthol is trapped to form an insoluble fluorescent product. The insolubility of the fluorescent product is of great importance here to prevent its diffusion from the cell. Such diffusion would not only lead to an underestimation of β-galactosidase activity in highly active cells but could also lead to an overestimation of enzyme activity in inactive cells or those with low activity, as they may take up the leaked fluorescent compound, thus reducing the apparent heterogeneity of the population.
- One group has described the use of a FACS machine in an assay detecting fusion proteins expressed from a specialized transducing bacteriophage in the prokaryote Bacillus subtilis (Chung, et. al., J. of Bacteriology, April 1994, p. 1977-1984; Chung, et. al., Biotechnology and Bioengineering, Vol. 47, pp. 234-242 (1995)). This group monitored the expression of a lacZ gene (encodes b-galactosidase) fused to the sporulation loci in subtilis (spo). The technique used to monitor b-galactosidase expression from spo-lacZ fusions in single cells involved taking samples from a sporulating culture, staining them with a commercially available fluorogenic substrate for b-galactosidase called C8-FDG, and quantitatively analyzing fluorescence in single cells by flow cytometry. In this study, the flow cytometer was used as a detector to screen for the presence of the spo gene during the development of the cells. The device was not used to screen and recover positive cells from a gene expression library or nucleic acid for the purpose of discovery.
- Another group has utilized flow cytometry to distinguish between the developmental stages of the delta-proteobacteria Myxococcus xanthus (F. Russo-Marie, et. al., PNAS, Vol. 90, pp. 8194-8198, September 1993). As in the previously described study, this study employed the capabilities of the FACS machine to detect and distinguish genotypically identical cells in different development regulatory states. The screening of an enzymatic activity was used in this study as an indirect measure of developmental changes.
- The lacZ gene from E. coli is often used as a reporter gene in studies of gene expression regulation, such as those to determine promoter efficiency, the effects of trans-acting factors, and the effects of other regulatory elements in bacterial, yeast, and animal cells. Using a chromogenic substrate, such as ONPG (o-nitrophenyl-(-D-galactopyranoside), one can measure expression of β-galactosidase in cell cultures; but it is not possible to monitor expression in individual cells and to analyze the heterogeneity of expression in cell populations. The use of fluorogenic substrates, however, makes it possible to determine β-galactosidase activity in a large number of individual cells by means of flow cytometry. This type of determination can be more informative with regard to the physiology of the cells, since gene expression can be correlated with the stage in the mitotic cycle or the viability under certain conditions. In 1994, Plovins, A., et al reported the use of fluorescein-Di-β-D-galactopyranoside (FDG) and C12-FDG as substrates for β-galactosidase detection in animal, bacterial, and yeast cells. This study compared the two molecules as substrates for β-galactosidase, and concluded that FDG is a better substrate for β-galactosidase detection by flow cytometry in bacterial cells. The screening performed in this study was for the comparison of the two substrates. The detection capabilities of a FACS machine were employed to perform the study on viable bacterial cells.
- Cells with chromogenic or fluorogenic substrates yield colored and fluorescent products, respectively. Previously, it had been thought that the flow cytometry-fluorescence-activated cell sorter approaches could be of benefit only for the analysis of cells that contain intracellularly, or are normally physically associated with, the enzymatic activity of small molecule of interest. On this basis, one could only use fluorogenic reagents which could penetrate the cell and which are thus potentially cytotoxic. To avoid clumping of heterogeneous cells, it is desirable in flow cytometry to analyze only individual cells, and this could limit the sensitivity and therefore the concentration of target molecules that can be sensed. Weaver and his colleagues at MIT and others have developed the use of gel microdroplets containing (physically) single cells which can take up nutrients, secret products, and grow to form colonies. The diffusional properties of gel microdroplets may be made such that sufficient extracellular product remains associated with each individual gel microdroplet, so as to permit flow cytometric analysis and cell sorting on the basis of concentration of secreted molecule within each microdroplet. Beads have also been used to isolate mutants growing at different rates, and to analyze antibody secretion by hybridoma cells and the nutrient sensitivity of hybridoma cells. The gel microdroplet method has also been applied to the rapid analysis of mycobacterial growth and its inhibition by antibiotics.
- The gel microdroplet technology has had significance in amplifying the signals available in flow cytometric analysis, and in permitting the screening of microbial strains in strain improvement programs for biotechnology. Wittrup et. al.(Biotechnolo. Bioeng. (1993) 42:351-356) developed a microencapsulation selection method which allows the rapid and quantitative screening of >10 6 yeast cells for enhanced secretion of Aspergillus awamori glucoamylase. The method provides a 400-fold single-pass enrichment for high-secretion mutants.
- Gel microdroplet or other related technologies can be used in the present invention to localize as well as amplify signals in the high throughput screening of recombinant libraries. Cell viability during the screening is not an issue or concern since nucleic acid can be recovered from the microdroplet.
- Different types of encapsulation strategies and compounds or polymers can be used with the present invention. For instance, high temperature agaroses can be employed for making microdroplets stable at high temperatures, allowing stable encapsulation of cells subsequent to heat kill steps utilized to remove all background activities when screening for thermostable bioactivities.
- There are several hurdles which must be overcome when attempting to detect and sort E. coli expressing recombinant enzymes, and recover encoding nucleic acids. FACS systems have typically been based on eukaryotic separations and have not been refined to accurately sort single E. coli cells; the low forward and sideward scatter of small particles like E. coli, reduces the ability of accurate sorting; enzyme substrates typically used in automated screening approaches, such as umbelifferyl based substrates, diffuse out of E. coli at rates which interfere with quantitation. Furthermore, recovery of very small amounts of DNA from sorted organisms can be problematic. The present invention addresses and overcomes these hurdles and offers a novel screening approach.
- The present invention adapts traditional eukaryotic flow cytometry cell sorting systems to high throughput screening for expression clones in prokaryotes. In the present invention, expression libraries derived from DNA, primarily DNA directly isolated from the environment, are screened very rapidly for bioactivities of interest utilizing fluorescense activated cell sorting. These libraries can contain greater than 10 8 members and can represent single organisms or can represent the genomes of over 100 different microorganisms, species or subspecies.
- This invention differs from fluorescense activated cell sorting, as normally performed, in several aspects. Previously, FACS machines have been employed in the studies focused on the analyses of eukaryotic and prokaryotic cell lines and cell culture processes. FACS has also been utilized to monitor production of foreign proteins in both eukaryotes and prokaryotes to study, for example, differential gene expression, etc. The detection and counting capabilities of the FACS system have been applied in these examples. However, FACS has never previously been employed in a discovery process to screen for and recover bioactivities in prokaryotes. Furthermore, the present invention does not require cells to survive, as do previously described technologies, since the desired nucleic acid (recombinant clones) can be obtained from alive or dead cells. The cells only need to be viable long enough to produce the compound to be detected, and can thereafter be either viable or non-viable cells so long as the expressed biomolecule remains active. The present invention also solves problems that would have been associated with detection and sorting of E. coli expressing recombinant enzymes, and recovering encoding nucleic acids. Additionally, the present invention includes within its embodiments any apparatus capable of detecting flourescent wavelengths associated with biological material, such apparatii are defined herein as fluorescent analyzers (one example of which is a FACS).
- The use of a culture-independent approach to directly clone genes encoding novel enzymes from environmental samples allows one to access untapped resources of biodiversity. The approach is based on the construction of “environmental libraries” which represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. Because the cloned DNA is initially extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species.
- In the evaluation of complex environmental expression libraries, a rate limiting step previously occurred at the level of discovery of bioactivities. The present invention allows the rapid screening of complex environmental expression libraries, containing, for example, thousands of different organisms. The analysis of a complex sample of this size requires one to screen several million clones to cover this genomic biodiversity. The invention represents an extremely high-throughput screening method which allows one to assess this enormous number of clones. The method disclosed allows the screening of at least about 36 million clones per hour for a desired biological activity. This allows the thorough screening of environmental libraries for clones expressing novel biomolecules.
- In the present invention, for example, gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest. Expression gene libraries are generated, clones are either exposed to the substrate or substrate(s) of interest, hybridized to a probe of interest, or bound to a detectable ligand and positive clones are identified and isolated via fluorescence activated cell sorting. Cells can be viable or non-viable during the process or at the end of the process, as nucleic acid encoding a positive activity can be isolated and cloned utilizing techniques well known in the art.
- Accordingly, in one aspect, the present invention provides a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nucleic acid directly isolated from the environment; and (ii) screening said libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify said clones.
- More particularly, the invention provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries made to contain nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify clones which react with the substrate or substrates.
- In another aspect, the invention also provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; and (ii) screening said exposed libraries utilizing an assay requiring a binding event or the covalent modification of a target, and a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify positive clones.
- FIG. 1 illustrates the substrate spectrum fingerprints and optimum reaction temperatures of five of novel esterases showing the diversity in these enzymes. EST# indicates the different enzyme; the temperatures indicate the optimal growth temperatures for the organisms from which the esterases were isolated; “E” indicates the relative activity of each esterase enzyme on each of the given substrates indicated (Hepanoate being the reference).
- FIG. 2 illustrates the cloning of DNA fragments prepared by random cleavage of target DNA to generate a representative library as described in Example 1.
- FIG. 3. In order to assess the total number of clones to be tested (e.g. the number of genome equivalents) a statistical analysis was performed. Assuming that mechanical shearing and gradient purification results in normal distribution of DNA fragment sizes with a mean of 4.5 kbp and variance of 1 kbp, the fraction represented of all possible 1 kbp sequences in a 1.8 Mbp genome is plotted in FIG. 3 as a function of increasing genome equivalents.
- FIG. 4 illustrates the protocol used in the cell sorting method of the invention to screen for recombinant enzymes, in this case using a (library excised into E. coli. The expression clones of interest are isolated by sorting. The procedure is described in detail in Examples 1, 3 and 4.
- FIG. 5 shows β-galactosidase clones stained with three different substrates: fluorescein-di-β-D-galactopyranoside (FDG), C12-fluorescein-di-β-D-galactopyranoside (C12FDG), chloromethyl-fluorescein-di-β-D-galactopyranoside (CMFDG). E. coli expressing β-galactosidase from Sulfulobus sulfotaricus species was grown overnight. Cells were centrifuged and substrate was loaded with deionized water. After five (5) minutes cells were centrifuged and transferred into HEPES buffer and heated to 70° C for thirty (30) minutes. Cells were spotted onto a slide and exposed to UV light. This illustrates the results of the experiments described in Example 3.
- FIG. 6 shows a microtiter plate where E. coli cells sorted in accordance with the invention are dispensed, one cell per well and grown up as clones which are then stained with fluorescein-di-β-D-galactopyranoside (FDG) (10 mM). This illustrates the results of the experiments described in Example 5.
- FIG. 7 shows the principle type of fluorescence enzyme assay of deacylation.
- FIG. 8 shows staining of β-galactosidase clones from the hyperthermophilic archaeon Sulfolobus solfataricus expressed in E. coli using C12-FDG as enzyme substrate.
- FIG. 9 shows the synthesis of 5-dodecanoyl-aminofluorescein-di-dodecanoic acid.
- FIG. 10 shows Rhodamine protease substrate.
- FIG. 11 shows a compound and process that can be used in the detection of monooxygenases.
- FIG. 12 is a schematic illustration of combinatorial enzyme development using directed evolution.
- FIG. 13 is a schematic illustration showing bypassing barriers to directed evolution.
- The method of the present invention begins with the construction of gene libraries which represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts.
- The microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. Libraries may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism. Such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, alkalophiles, acidophiles, etc.
- Sources of microorganism DNA as a starting material library from which target DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. Thus, for example, genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme or other biological activity. Prokaryotic expression libraries created from such starting material which includes DNA from more than one species are defined herein as multispecific libraries.
- In one embodiment, viable or non-viable cells isolated from the environment are, prior to the isolation of nucleic acid for generation of the expression gene library, FACS sorted to separate prokaryotic cells from the sample based on, for instance, DNA or AT/GC content of the cells. Various dyes or stains well known in the art, for example those described in “Practical Flow Cytometry”, 1995 Wiley-Liss, Inc., Howard M. Shapiro, M.D., are used to intercalate or associate with nucleic acid of cells, and cells are separated on the FACS based on relative DNA content or AT/GC DNA content in the cells. Other criteria can also be used to separate prokaryotic cells from the sample, as well. DNA is then isolated from the cells and used for the generation of expression gene libraries, which are then screened using the FACS for activities of interest.
- Alternatively, the nucleic acid is isolated directly from the environment and is, prior to generation of the gene library, sorted based on DNA or AT/GC content. DNA isolated directly from the environment, is used intact, randomly sheared or digested to general fragmented DNA. The DNA is then bound to an intercalating agent as described above, and separated on the analyzer based on relative base content to isolate DNA of interest. Sorted DNA is then used for the generation of gene libraries, which are then screened using the analyzer for activities of interest.
- The present invention can further optimize methods for isolation of activities of interest from a variety of sources, including consortias of microorganisms, primary enrichments, and environmental “uncultivated” samples, to make libraries which have been “normalized” in their representation of the genome populations in the original samples. and to screen these libraries for enzyme and other bioactivities. Libraries with equivalent representation of genomes from microbes that can differ vastly in abundance in natural populations are generated and screened. This “normalization” approach reduces the redundancy of clones from abundant species and increases the representation of clones from rare species. These normalized libraries allow for greater screening efficiency resulting in the identification of cells encoding novel biological catalysts.
- One embodiment for forming a normalized library from an environmental sample begins with the isolation of nucleic acid from the sample. This nucleic acid can then be fractionated prior to normalization to increase the chances of cloning DNA from minor species from the pool of organisms sampled. DNA can be fractionated using a density centrifugation technique, such as a cesium-chloride gradient. When an intercalating agent, such as bis-benzimide is employed to change the buoyant density of the nucleic acid, gradients will fractionate the DNA based on relative base content. Nucleic acid from multiple organisms can be separated in this manner, and this technique can be used to fractionate complex mixtures of genomes. This can be of particular value when working with complex environmental samples. Alternatively, the DNA does not have to be fractionated prior to normalization. Samples are recovered from the fractionated DNA, and the strands of nucleic acid are then melted and allowed to selectively reanneal under fixed conditions (C ot driven hybridization). When a mixture of nucleic acid fragments is melted and allowed to reanneal under stringent conditions, the common sequences find their complementary strands faster than the rare sequences. After an optional single-stranded nucleic acid isolation step, single-stranded nucleic acid representing an enrichment of rare sequences is amplified using techniques well known in the art, such as a polymerase chain reaction (Barnes, 1994), and used to generate gene libraries. This procedure leads to the amplification of rare or low abundance nucleic acid molecules, which are then used to generate a gene library which can be screened for a desired bioactivity. While DNA will be recovered, the identification of the organism(s) originally containing the DNA may be lost. This method offers the ability to recover DNA from “unclonable” sources.
- Hence, one embodiment for forming a normalized library from environmental sample(s) is by (a) isolating nucleic acid from the environmental sample(s); (b) optionally fractionating the nucleic acid and recovering desired fractions; (c) normalizing the representation of the DNA within the population so as to form a normalized expression library from the DNA of the environmental sample(s). The “normalization” process is described and exemplified in detail in co-pending, commonly assigned U.S. Ser. No. 08/665,565, filed Jun. 18, 1996.
- The preparation of DNA from the sample is an important step in the generation of normalized or non-normalized DNA libraries from environmental samples composed of uncultivated organisms, or for the generation of libraries from cultivated organisms. DNA can be isolated from samples using various techniques well known in the art (Nucleic Acids in the Environment Methods & Applications, J. T. Trevors, D. D. van Elsas, Springer Laboratory, 1995). Preferably, DNA obtained will be of large size and free of enzyme inhibitors or other contaminants. DNA can be isolated directly from an environmental sample (direct lysis), or cells may be harvested from the sample prior to DNA recovery (cell separation) . Direct lysis procedures have several advantages over protocols based on cell separation. The direct lysis technique provides more DNA with a generally higher representation of the microbial community, however, it is sometimes smaller in size and more likely to contain enzyme inhibitors than DNA recovered using the cell separation technique. Very useful direct lysis techniques have been described which provide DNA of high molecular weight and high purity (Barns, 1994; Holben, 1994). If inhibitors are present, there are several protocols which utilize cell isolation which can be employed (Holben, 1994). Additionally, a fractionation technique, such as the bis-benzimide separation (cesium chloride isolation) described, can be used to enhance the purity of the DNA.
- Isolation of total genomic DNA from extreme environmental samples varies depending on the source and quantity of material. Uncontaminated, good quality (>20 kbp) DNA is required for the construction of a representative library. A successful general DNA isolation protocol is the standard cetyl-trimethyl-ammonium-bromide (CTAB) precipitation technique. A biomass pellet is lysed and proteins digested by the nonspecific protease, proteinase K, in the presence of the detergent SDS. At elevated temperatures and high salt concentrations, CTAB forms insoluble complexes with denatured protein, polysaccharides and cell debris. Chloroform extractions are performed until the white interface containing the CTAB complexes is reduced substantially. The nucleic acids in the supernatant are precipitated with isopropanol and resuspended in TE buffer.
- For cells which are recalcitrant to lysis, a combination of chemical and mechanical methods with cocktails of various cell-lysing enzymes may be employed. Isolated nucleic acid may then further be purified using small cesium gradients.
- Gene libraries can be generated by inserting the DNA isolated or derived from a sample into a vector or a plasmid. Such vectors or plasmids are preferably those containing expression regulatory sequences, including promoters, enhancers and the like. Such polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmids and methods for introduction and packaging into them are described herein.
- The following outlines a general procedure for producing libraries from both culturable and non-culturable organisms:
- Obtain Biomass
- DNA Isolation (various methods)
- Shear DNA (for example, with a 25 gauge needle)
- Blunt DNA
- Methylate DNA
- Ligate to linkers
- Cut back linkers
- Size Fractionate (for example, use a Sucrose Gradient)
- Ligate to lambda expression vector
- Package (in vitro lambda packaging extract)
- Plate on E. coli host and amplify
- As detailed in FIG. 1, cloning DNA fragments prepared by random cleavage of the target DNA generates a representative library. DNA dissolved in TE buffer is vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments are in the desired size range. The DNA ends are “polished” or blunted with Mung Bean Nuclease, and EcoRI restriction sites in the target DNA are protected with EcoRI Methylase. EcoRI linkers (GGAATTCC) are ligated to the blunted/protected DNA using a very high molar ratio of linkers to target DNA. This lowers the probability of two DNA molecules ligating together to create a chimeric clone. The linkers are cut back with EcoRI restriction endonuclease and the DNA is size fractionated. The removal of sub-optimal DNA fragments and the small linkers is critical because ligation to the vector will result in recombinant molecules that are unpackageable, or the construction of a library containing only linkers as inserts. Sucrose gradient fractionation is used since it is extremely easy, rapid and reliable. Although the sucrose gradients do not provide the resolution of agarose gel isolations, they do produce DNA that is relatively free of inhibiting contaminants. The prepared target DNA is ligated to the lambda vector, packaged using in vitro packaging extracts and grown on the appropriate E. coli.
- As representative examples of expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.) Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, PBPV, PMSG, pSVLSV40 (Pharmacia). However, any other plasmid or other vector may be used as long as they are replicable and viable in the host.
- Another type of vector for use in the present invention contains an f-factor origin replication. The f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. A particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P R, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), (-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- The cloning strategy permits expression via both vector driven and endogenous promoters; vector promotion may be important with expression of genes whose endogenous promoter will not function in E. coli.
- The DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- The DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity. The selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity. The host cell is a prokaryotic cell, such as a bacterial cell. Particularly preferred host cells are E. coli. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)). The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- It is also contemplated that expression libraries generated can be phage display or cell surface display libraries. Numerous techniques are published in the art for generating such libraries.
- After the expression libraries have been generated one can include the additional step of “biopanning” such libraries prior to screening by cell sorting. The “biopanning” procedure refers to a process for identifying clones having a specified biological activity by screening for sequence homology in a library of clones prepared by (i) selectively isolating target DNA, from DNA derived from at least one microorganism, by use of at least one probe DNA comprising at least a portion of a DNA sequence encoding an biological having the specified biological activity; and (ii) transforming a host with isolated target DNA to produce a library of clones which are screened for the specified biological activity.
- The probe DNA used for selectively isolating the target DNA of interest from the DNA derived from at least one microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding an enzyme having the specified enzyme activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.
- The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which target DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate target DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- Preferably the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the target DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- The resultant libraries of transformed clones are then screened for clones which display activity for the enzyme of interest.
- Having prepared a multiplicity of clones from DNA selectively isolated from an organism, such clones are screened for a specific enzyme activity and to identify the clones having the specified enzyme characteristics.
- The screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened utilizing a FACS machine for such enzyme activity or for a more specific activity. Alternatively, encapsulation techniques such as gel microdroplets, may be employed to localize multiple clones in one location to be screened on a FACS machine for positive expressing clones within the group of clones which can then be broken out into individual clones to be screened again on a FACS machine to identify positive individual clones. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened utilizing a FACS machine to determine which of such clones has hydrolase activity.
- As described with respect to one of the above aspects, the invention provides a process for enzyme activity screening of clones containing selected DNA derived from a microorganism which process comprises:
- screening a library for specified enzyme activity, said library including a plurality of clones, said clones having been prepared by recovering from genomic DNA of a microorganism selected DNA, which DNA is selected by hybridization to at least one DNA sequence which is all or a portion of a DNA sequence encoding an enzyme having the specified activity; and
- transforming a host with the selected DNA to produce clones which are screened for the specified enzyme activity.
- In one embodiment, a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by:
- (a) rendering the double-stranded genomic DNA population into a single-stranded DNA population;
- (b) contacting the single-stranded DNA population of (a) with the DNA probe bound to a ligand under conditions permissive of hybridization so as to produce a double-stranded complex of probe and members of the genomic DNA population which hybridize thereto;
- (c) contacting the double-stranded complex of (b) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;
- (d) separating the solid phase complex from the single-stranded DNA population of (b);
- (e) releasing from the probe the members of the genomic population which had bound to the solid phase bound probe;
- (f) forming double-stranded DNA from the members of the genomic population of (e);
- (g) introducing the double-stranded DNA of (f) into a suitable host to form a library containing a plurality of clones containing the selected DNA; and
- (h) screening the library for the specified enzyme activity.
- In another aspect, the process includes a preselection to recover DNA including signal or secretion sequences. In this manner it is possible to select from the genomic DNA population by hybridization as hereinabove described only DNA which includes a signal or secretion sequence. The following paragraphs describe the protocol for this embodiment of the invention, the nature and function of secretion signal sequences in general and a specific exemplary application of such sequences to an assay or selection process.
- A particularly preferred embodiment of this aspect further comprises, after (a) but before (b) above, the steps of:
- (a i). contacting the single-stranded DNA population of (a) with a ligand-bound oligonucleotide probe that is complementary to a secretion signal sequence unique to a given class of proteins under conditions permissive of hybridization to form a double-stranded complex;
- (a ii). contacting the double-stranded complex of (a i) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;
- (a iii) separating the solid phase complex from the single-stranded DNA population of (a);
- (a iv) releasing the members of the genomic population which had bound to said solid phase bound probe; and
- (a v) separating the solid phase bound probe from the members of the genomic population which had bound thereto.
- The DNA which has been selected and isolated to include a signal sequence is then subjected to the selection procedure hereinabove described to select and isolate therefrom DNA which binds to one or more probe DNA sequences derived from DNA encoding an enzyme(s) having the specified enzyme activity.
- This procedure is described and exemplified in U.S. Ser. No. 08/692,002, filed Aug. 2, 1996.
- In-vivo biopanning may be performed utilizing a FACS-based machine. Complex gene libraries are constructed with vectors which contain elements which stabilize transcribed RNA. For example, the inclusion of sequences which result in secondary structures such as hairpins which are designed to flank the transcribed regions of the RNA would serve to enhance their stability, thus increasing their half life within the cell. The probe molecules used in the biopanning process consist of oligonucleotides labeled with reporter molecules that only fluoresce upon binding of the probe to a target molecule (e.g. molecular beacons—see ref.). These probes are introduced into the recombinant cells from the library using one of several transformation methods. The probe molecules bind to the transcribed target mRNA resulting in DNA/RNA heteroduplex molecules. Binding of the probe to a target will yield a fluorescent signal which is detected and sorted by the FACS machine during the screening process.
- Further, it is possible to combine all the above embodiments such that a normalization step is performed prior to generation of the expression library, the expression library is then generated, the expression library so generated is then biopanned, and the biopanned expression library is then screened using a high throughput cell sorting and screening instrument. Thus there are a variety of options: i.e. (i) one can just generate the library and then screen it; (ii) normalize the target DNA, generate the expression library and screen it; (iii) normalize, generate the library, biopan and screen; or (iv) generate, biopan and screen the library.
- The library may, for example, be screened for a specified enzyme activity. For example, the enzyme activity screened for may be one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases. The recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- Alternatively, the library may be screened for a more specialized enzyme activity. For example, instead of generically screening for hydrolase activity, the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- The clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity. Thus, in accordance with the present invention it is possible to isolate and identify: (i) DNA encoding an enzyme having a specified enzyme activity, (ii) enzymes having such activity (including the amino acid sequence thereof) and (iii) produce recombinant enzymes having such activity.
- The present invention may be employed for example, to identify new enzymes having, for example, the following activities which may be employed for the following uses:
- Lipase/Esterase
- Enantioselective hydrolysis of esters (lipids)/thioesters
- Resolution of racemic mixtures
- Synthesis of optically active acids or alcohols from meso-diesters
- Selective syntheses
- Regiospecific hydrolysis of carbohydrate esters
- Selective hydrolysis of cyclic secondary alcohols
- Synthesis of optically active esters, lactones, acids, alcohols
- Transesterification of activated/nonactivated esters
- Interesterification
- Optically active lactones from hydroxyesters
- Regio- and enantioselective ring opening of anhydrides
- Detergents
- Fat/Oil conversion
- Cheese ripening
- Protease
- Ester/amide synthesis
- Peptide synthesis
- Resolution of racemic mixtures of amino acid esters
- Synthesis of non-natural amino acids
- Detergents/protein hydrolysis
- Glycosidase/Glycosyl transferase
- Sugar/polymer synthesis
- Cleavage of glycosidic linkages to form mono, di- and oligosaccharides
- Synthesis of complex oligosaccharides
- Glycoside synthesis using UDP-galactosyl transferase
- Transglycosylation of disaccharides, glycosyl fluorides, aryl galactosides
- Glycosyl transfer in oligosaccharide synthesis
- Diastereoselective cleavage of (-glucosylsulfoxides
- Asymmetric glycosylations
- Food processing
- Paper processing
- Phosphatase/Kinase
- Synthesis/hydrolysis of phosphate esters
- Regio-, enantioselective phosphorylation
- Introduction of phosphate esters
- Synthesize phospholipid precursors
- Controlled polynucleotide synthesis
- Activate biological molecule
- Selective phosphate bond formation without protecting groups
- Mono/Dioxygenase
- Direct oxyfunctionalization of unactivated organic substrates
- Hydroxylation of alkane, aromatics, steroids
- Epoxidation of alkenes
- Enantioselective sulphoxidation
- Regio- and stereoselective Bayer-Villiger oxidations
- Haloperoxidase
- Oxidative addition of halide ion to nucleophilic sites
- Addition of hypohalous acids to olefinic bonds
- Ring cleavage of cyclopropanes
- Activated aromatic substrates converted to ortho and para derivatives
- 1.3 diketones converted to 2-halo-derivatives
- Heteroatom oxidation of sulfur and nitrogen containing substrates
- Oxidation of enol acetates, alkynes and activated aromatic rings
- Lignin peroxidase/Diarylpropane peroxidase
- Oxidative cleavage of C—C bonds
- Oxidation of benzylic alcohols to aldehydes
- Hydroxylation of benzylic carbons
- Phenol dimerization
- Hydroxylation of double bonds to form diols
- Cleavage of lignin aldehydes
- Epoxide hydrolase
- Synthesis of enantiomerically pure bioactive compounds
- Regio- and enantioselective hydrolysis of epoxide
- Aromatic and olefinic epoxidation by monooxygenases to form epoxides
- Resolution of racemic epoxides
- Hydrolysis of steroid epoxides
- Nitrile hydratase/nitrilase
- Hydrolysis of aliphatic nitrites to carboxamides
- Hydrolysis of aromatic, heterocyclic, unsaturated aliphatic nitrites to corresponding acids
- Hydrolysis of acrylonitrile
- Production of aromatic and carboxamides, carboxylic acids (nicotinamide, picolinamide, isonicotinamide)
- Regioselective hydrolysis of acrylic dinitrile (-amino acids from (-hydroxynitriles
- Transaminase
- Transfer of amino groups into oxo-acids
- Amidase/Acylase
- Hydrolysis of amides, amidines, and other C—N bonds
- Non-natural amino acid resolution and synthesis
- As indicated, the present invention also offers the ability to screen for other types of bioactivities. For instance, the ability to select and combine desired components from a library of polyketides and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing. The method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide synthases, since one can generate gene banks with clones containing large inserts (especially when using vectors which can accept large inserts, such as the f-factor based vectors), which facilitates cloning of gene clusters.
- Preferably, the gene cluster or pathway DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli. As previously indicated, this f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples. Other examples of vectors include cosmids, bacterial artificial chromosome vectors, and P1 vectors.
- Lambda vectors can also accommodate relatively large DNA molecules, have high cloning and packaging efficiencies and are easy to handle and store compared to plasmid vectors. (-ZAP vectors (Stratagene Cloning Systems, Inc.) have a convenient subcloning feature that allows clones in the vector to be excised with helper phage into the pBluescript phagemid, eliminating the time involved in subcloning. The cloning site in these vectors lies downstream of the lac promoter. This feature allows expression of genes whose endogenous promoter does not function in E. coli.
- The following describes the total number of assays required to test an entire library:
- The two main factors which govern the total number of clones that can be pooled and simultaneously screened are (i) the level of gene expression and (ii) enzyme assay sensitivity. As estimate of the level of gene expression is that each E. coli cell infected with lambda will produce 103 copies of the gene product from the insert. FACS instruments are sufficiently sensitive to detect about 500 to 1000 Fluorescein molecules.
- In order to assess the total number of clones to be tested (e.g., the number of genome equivalents) a statistical analysis was performed. Assuming that mechanical shearing and gradient purification results in a normal distribution of DNA fragment sizes with a mean of 4.5 kbp and variance of 1 kbp, the fraction represented of all possible 1 kbp sequences in a 1.8 Mbp genome is plotted in FIG. 3 as a function of increasing genome equivalents.
- Based on these results, approximately 2,000 clones (5 genome equivalents) must be screened to achieve a ˜90% probability of obtaining a particular gene. This represents the point of maximal efficiency for library throughput. Assuming that a complex environmental library contains about 1000 different organisms, at least 2,000,000 clones have to be screened to achieve a >90% probability of obtaining a particular gene. This number rises dramatically assuming that the organisms differ vastly in abundance in natural populations.
- Substrate can be administered to the cells before or during the process of the cell sorting analysis. In either case a solution of the substrate is made up and the cells are contacted therewith. When done prior to the cell sorting analysis this can be by making a solution which can be administered to the cells while in culture plates or other containers. The concentration ranges for substrate solutions will vary according to the substrate utilized. Commercially available substrates will generally contain instructions on concentration ranges to be utilized for, for instance, cell staining purposes. These ranges may be employed in the determination of an optimal concentration or concentration range to be utilized in the present invention. The substrate solution is maintained in contact with the cells for a period of time and at an appropriate temperature necessary for the substrate to permeablize the cell membrane. Again, this will vary with substrate. Instruments which deliver reagents in stream such as by poppet valves which seal openings in the flow path until activated to permit introduction of reagents (e.g. substrate) into the flow path in which the cells are moving through the analyzer can be employed for substrate delivery.
- The substrate is one which is able to enter the cell and maintain its presence within the cell for a period sufficient for analysis to occur. It has generally been observed that introduction of the substrate into the cell across the cell membrane occurs without difficulty. It is also preferable that once the substrate is in the cell it not “leak” back out before reacting with the biomolecule being sought to an extent sufficient to product a detectable response. Retention of the substrate in the cell can be enhanced by a variety of techniques. In one, the substrate compound is structurally modified by addition of a hydrophobic tail. In another certain preferred solvents, such as DMSO or glycerol, can be administered to coat the exterior of the cell. Also the substrate can be administered to the cells at reduced temperature which has been observed to retard leakage of the substrate from the cell's interior.
- A broad spectrum of substrates can be used which are chosen based on the type of bioactivity sought. In addition where the bioactivity being sought is in the same class as that of other biomolecules for which a number have known substrates, the bioactivity can be examined using a cocktail of the known substrates for the related biomolecules which are already known. For example, substrates are known for approximately 20 commercially available esterases and the combination of these known substrates can provide detectable, if not optimal, signal production. Substrates are also known and available for glycosidases, proteases, phosphatases, and monoxygenases.
- The substrate interacts with the target biomolecule so as to produce a detectable response. Such responses can include chromogenic or fluorogenic responses and the like. The detectable species can be one which results from cleavage of the substrate or a secondary molecule which is so affected by the cleavage or other substrate/biomolecule interaction to undergo a detectable change. Innumerable examples of detectable assay formats are known from the diagnostic arts which use immunoassay, chromogenic assay, and labeled probe methodologies.
- Several enzyme assays described in the literature are built around the change in fluorescence which results when the phenolic hydroxyl (or anilino amine) becomes deacylated (or dealkylated) by the action of the enzyme. FIG. 7 shows the basic principle for this type of enzyme assay for deacylation. Any emission or activation of fluorescent wavelengths as a result of any biological process are defined herein as bioactive fluoresence.
- In comparison to calorimetric assays, fluorescent based assays are very sensitive, which is a major criteria for single cell assays. There are two main factors which govern the screening of a recombinant enzyme in a single cell: i) the level of gene expression, and ii) enzyme assay sensitivity. To estimate the level of gene expression one can determine how many copies of the gene product will be produced by the host cell given the vector. For instance, one can assume that each E. coli cell infected with pBluescript phagemid (Stratagene Cloning Systems, Inc.) will produce ˜103 copies of the gene product from the insert. The FACS instruments are capable of detecting about 500 to 1,000 fluorescein molecules per cell. Assuming that one enzyme turns over at least one fluorescein based substrate molecule, one cell will display enough fluorescence to be detected by the optics of a fluorescence-activated cell sorter (FACS).
- Several methods have been described for using reporter genes to measure gene expression. These reporter genes encode enzymes not ordinarily found in the type of cell being studied, and their unique activity is monitored to determine the degree of transcription. Nolan et al., developed a technique to analyze (-galactosidase expression in mammalian cells employing fluorescein-di-(-D-galactopyranoside (FDG) as a substrate for (-galactosidase, which releases fluorescein, a product that can be detected by a fluorescence-activated cell sorter (FACS) upon hydrolysis (Nolan et al., 1991). A problem with the use of FDG is that if the assay is performed at room temperature, the fluorescence leaks out of the positively stained cells. A similar problem was encountered in other studies of (-galactosidase measurements in mammalian cells and yeast with FDG as well as other substrates (Nolan et al, 1988; Wittrup et al., 1988). Performing the reaction at 0° C. appreciably decreased the extent of this leakage of fluorescence (Nolan et al., 1988). However this low temperature is not adaptable for screening for, for instance, high temperature (-galactosidases. Other fluorogenic substrates have been developed, such as 5-dodecanoylamino fluorescein di-(-D-galactopyranoside (C 12-FDG) (Molecular Probes) which differs from FDG in that it is a lipophilic fluorescein derivative that can easily cross most cell membranes under physiological culture conditions. The green fluorescent enzymatic hydrolysis product is retained for hours to days in the membrane of those cells that actively express the lacZ reporter gene. In animal cells C12-FDG was a much better substrate, giving a signal which was 100 times higher than the one obtained with FDG (Plovins et al., 1994). However in Gram negative bacteria like E. coli, the outer membrane functions as a barrier for the lipophilic molecule C12-FDG and it only passes through this barrier if the cells are dead or damaged (Plovins et al). The fact that C12 retains FDG substrate inside the cells indicates that the addition of unpolarized tails may be used for retaining substrate inside the cells with respect to other enzyme substrates.
- The abovementioned (-galactosidase assays may be employed to screen single E. coli cells, expressing recombinant (-D-galactosidase isolated from a hyperthermophilic archaeon such as Sulfolobus solfataricus, on a fluorescent microscope. Cells are cultivated overnight, centrifuged and washed in deionized water and stained with FDG. To increase enzyme activity, cells are heated to 70° C. for 30 minutes and examined with a fluorescence phase contrast microscope. E. coli cell suspensions of the (-galactosidase expressing clone stained with C12-FDG show a very bright fluorescence inside single cells (FIG. 8).
- The heat treatment of E. coli permeabilizes the cells to allow the substrate to pass through the membrane. Control strains containing plasmid DNA without insert and stained with the same procedure show no fluorescence. Phase contrast microscopy of heated cells reveals that cells maintain their structural integrity up to 2 hours if heated up to 70° C. The lipophilic tail of the modified fluorescein-di-(-D-galactopyranoside prevents leakage of the molecule, even at elevated temperatures. The attachment of a lipophilic carbon chain changes the solubility of substrates tremendously. Thus, substrates containing lipophilic carbon chains can be generated and utilized as screening substrates in the present invention. For instance, the following activities may be detected utilized the indicated substrates. Different methods can be employed for loading substrate inside the cells. Additionally, DMSO can be used as solvent up to a concentration of 50% in water to dissolve and load substrates without significantly dropping the viability of E. coli. Enzyme activity and leakage can be monitored with fluorescence microscopy.
- Lipases/Esterases
- An acylated derivative of fluorescein can be used to detect esterases such as lipases. The fluorophore is hydrolyzed from the derivative to generate a signal. Acylated derivatives of fluorescein can be synthesized according to FIG. 9. Nine molar equivalents of lauric anhydride triethylamine and N,N-diisopropylethylamine are added to a solution of fluoresceinamine in chloroform. After the reaction is complete, the product 5-dodecanoyl-aminofluorescein-di-dodecanoic acid (C 12-FDC12) is recrystallized.
- Proteases
- Proteases can be assayed in the same way as the esterases, with an amide being cleaved instead of an ester. There are now well over 100 different protease substrates available with an acylated fluorophore at the scissile bond. Rhodamine derivatives (FIG. 10), have more lipophilic characteristics compared to fluorescein protrease substrates, therefore they make good substrates for more general assays.
- Monooxygenases (Dealkylases)
- Compounds such as that depicted in FIG. 11 can be used to detected monooxygenases. Hydroxylation of the ethyl group in the compound results in the release of the resorufin fluorophore. Several unmodified coumarin derivatives are also commercially available.
- A variety of types of high throughput cell sorting instruments can be used with the present invention. First there is the FACS cell sorting instrument which has the advantage of a very high throughput and individual cell analysis. Other types of instruments which can be used are robotics instruments and time-resolved fluorescence instruments, which can actually measure the fluorescence from a single molecule over an elapsed period of time. Since they are measuring a single molecule, they can simultaneously determine its molecular weight, however their throughput is not as high as the FACS cell sorting instruments.
- When screening with the FACS instrument, the trigger parameter is set with logarithmic forward side scatter. The fluorescent signals of positive clones emitted by fluorescein or other fluorescent substrates is distinguished by means of a dichroic mirror and acquired in log mode. For example, “active” clones can be sorted and deposited into microtiter plates. When sorting clones from libraries constructed from single organisms or from small microbial consortia, approximately 50 clones can be sorted into individual microtiter plate wells. When complex environmental mega-libaries (i.e. libraries containing ˜10 8 clones which represent >100 organisms) about 500 expressing clones should be collected.
- Plasmid DNA can then be isolated from the sorted clones using any commercially available automated miniprep machine, such as that from Autogen. The plasmids are then retransformed into suitable expression hosts and assayed for activity utilizing chromogenic agar plate based or automated liquid format assays. Confirmed expression clones can then undergo RFLP analysis to determine unique clones prior to sequencing. The inserts which contain the unique esterase clones can be sequenced, open reading frames (ORF's) identified and the genes PCR subcloned for overexpression. Alternatively, expressing clones can be “bulk sorted” into single tubes and the plasmid inserts recovered as amplified products, which are then subcloned and transformed into suitable vector-hosts systems for rescreening.
- Encapsulation techniques may be employed to localize signal, even in cases where cells are no longer viable. Gel microdrops (GMDs) are small (25 to Sum in diameter) particles made with a biocompatible matrix. In cases of viable cells, these microdrops serve as miniaturized petri dishes because cell progeny are retained next to each other, allowing isolation of cells based on clonal growth. The basic method has a significant degree of automation and high throughput; after the colony size signal boundaries are established, about 10 6 GMDs per hour can be automatically processed. Cells are encapsulated together with substrates and particles containing a positive clones are sorted. Fluorescent substrate labeled glass beads can also be loaded inside the GMDs. In cases of non-viable cells, GMDs can be employed to ensure localization of signal.
- After viable or non-viable cells, each containing a different expression clone from the gene library are screened on a FACS machine, and positive clones are recovered, DNA is isolated from positive clones. The DNA can then be amplified either in vivo or in vitro by utilizing any of the various amplification techniques known in the art. In vivo amplification would include transformation of the clone(s) or subclone(s) of the clones into a viable host, followed by growth of the host. In vitro amplification can be performed using techniques such as the polymerase chain reaction.
- Clones found to have the bioactivity for which the screen was performed can also be subjected to directed mutagenesis to develop new bioactivities with desired properties or to develop modified bioactivities with particularly desired properties that are absent or less pronounced in the wild-type enzyme, such as stability to heat or organic solvents. Any of the known techniques for directed mutagenesis are applicable to the invention. For example, particularly preferred mutagenesis techniques for use in accordance with the invention include those described below.
- The term “error-prone PCR” refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Leung, D. W., et al., Technique, 1:11-15 (1989) and Caldwell, R. C. & Joyce G. F., PCR Methods Applic., 2:28-33 (1992).
- The term “oligonucleotide directed mutagenesis” refers to a process which allows for the generation of site-specific mutations in any cloned DNA segment of interest. Reidhaar-Olson, J. F. & Sauer, R. T., et al., Science, 241:53-57 (1988).
- The term “assembly PCR” refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.
- The term “sexual PCR mutagenesis” (also known as “DNA shuffling”) refers to forced homologous recombination between DNA molecules of different but highly related DNA sequence in vitro, caused by random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Stemmer, W. P., PNAS, USA, 91:10747-10751 (1994).
- The term “in vivo mutagenesis” refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of E. coli that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propogating the DNA in one of these strains will eventually generate random mutations within the DNA.
- The term “cassette mutagenesis” refers to any process for replacing a small region of a double stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.
- The term “recursive ensemble mutagenesis” refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Arkin, A. P. and Youvan, D. C., PNAS, USA, 89:7811-7815 (1992).
- The term “exponential ensemble mutagenesis” refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins, Delegrave, S. and Youvan, D. C., Biotechnology Research, 11:1548-1552 (1993); and random and site-directed mutagenesis, Arnold, F. H., Current Opinion in Biotechnology, 4:450-455 (1993).
- All of the references mentioned above are hereby incorporated by reference in their entirety. Each of these techniques is described in detail in the references mentioned.
- DNA can be mutagenized, or “evolved”, utilizing any one or more of these techniques, and rescreened on the FACS machine to identify more desirable clones. Internal control reference genes which either express fluorescing molecules, such as those encoding green fluorescent protein, or encode proteins that can turnover fluorescing molecules, such as beta-galactosidase, can be utilized. These internal controls should optimally fluoresce at a wavelength which is different from the wavelength at which the molecule used to detect the evolved molecule(s) emits. DNA is evolved, recloned in a vector which co-expresses these proteins or molecules, transformed into an appropriate host organism, and rescreened utilizing the FACS machine to identify more desirable clones.
- An important aspect of the invention is that cells are being analyzed individually. However other embodiments are contemplated which involve pooling of cells and multiple passage screen. This provides for a tiered analysis of biological activity from more general categories of activity, i.e. categories of enzymes, to specific activities of principle interest such as enzymes of that category which are specific to particular substrate molecules.
- Members of these libraries can be encapsulated in gel microdroplets, exposed to substrates of interest, such as transition state analogs, and screened based on binding via FACS sorting for activities of interest.
- It is anticipated with the present invention that one could employ mixtures of substrates to simultaneously detect multiple activities of interest simultaneously or sequentially. FACS instruments can detect molecules that fluoresce at different wavelengths, hence substrates which fluoresce at different wavelengths and indicate different activities can be employed.
- The fluorescence activated cell sorting screening method of the present invention allows one to assay several million clones per hour for a desired bioactivity. This technique provides an extremely high throughput screening process necessary for the screening of extreme biodiverse environmental libraries.
- The invention will now be illustrated by the following working examples, which are in no way a limitation thereof.
- The following outlines the procedures used to generate a gene library from an environmental sample.
- Isolate DNA.
- IsoQuick Procedure as per manufacturer's instructions (Orca, Research Inc., Bothell, Wash.).
- Normalization.
- DNA can be normalized according to Example 2.
- Shear DNA
- Vigorously push and pull DNA through a 25G double-hub needle and 1-cc syringes about 500 times.
- Check a small amount (0.5 (g) on a 0.8% agarose gel to make sure the majority of the DNA is in the desired size range (about 3-6 kb).
- Blunt DNA
- Add:
H2O to a final volume of 405 (l 45 (l 10X Mung Bean Buffer 2.0 (l Mung Bean Nuclease (150 u/(l) - Incubate 37(C, 15 minutes.
- Phenol/chloroform extract once.
- Chloroform extract once.
- Add 1 ml ice cold ethanol to precipitate.
- Place on ice for 10 minutes.
- Spin in microfuge, high speed, 30 minutes.
- Wash with 1 ml 70% ethanol.
- Spin in microfuge, high speed, 10 minutes and dry.
- Methylate DNA
- Gently resuspend DNA in 26 (l TE.
- Add:
4.0 (l 10X EcoR I Methylase Buffer 0.5 (l SAM (32 mM) 5.0 (l EcoR I Methylase (40 u/(l) - Incubate 37(, 1 hour.
- Insure Blunt Ends
- Add to the methylation reaction:
5.0 (l 100 mM MgCl2 8.0 (l dNTP mix (2.5 mM of each dGTP, dATP, dTTP, dCTP) 4.0 (l Klenow (5 u/(l) - Incubate 12(C, 30 minutes.
- Add 450 (
l 1× STE. - Phenol/chloroform extract once.
- Chloroform extract once.
- Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- Spin in microfuge, high speed, 30 minutes.
- Wash with 1 ml 70% ethanol.
- Spin in microfuge, high speed, 10 minutes and dry.
- Adaptor Ligation
- Gently resuspend DNA in 8 (l EcoRI adaptors (from Stratagene's cDNA Synthesis Kit).
- Add:
1.0 (l 10X Ligation Buffer 1.0 ( l 10 mM rATP 1.0 (l T4 DNA Ligase (4Wu/ (l) - Incubate 4(C, 2 days.
- Phosphorylate Adaptors
- Heat kill ligation reaction 70(C, 30 minutes.
- Add:
1.0 (l 10X Ligation Buffer 2.0 ( l 10 mM rATP 6.0 (l H2O 1.0 (l Polynucleotide kinase (PNK) - Incubate 37(C, 30 minutes.
- Add 31 (l H 2O and 5 (
l 10× STE. - Size fractionate on a Sephacryl S-500 spin column (pool fractions 1-3).
- Phenol/chloroform extract once.
- Chloroform extract once.
- Add ice cold ethanol to precipitate.
- Place on ice, 10 minutes.
- Spin in microfuge, high speed, 30 minutes.
- Wash with 1 ml 70% ethanol.
- Spin in microfuge, high speed, 10 minutes and dry.
- Resuspend in 10.5 (l TE buffer.
- Do not plate assay. Instead, ligate directly to arms as above except use 2.5 (l of DNA and no water.
- Sucrose Gradient (2.2 ml) Size Fractionation
- Heat sample to 65(C, 10 minutes.
- Gently load on 2.2 ml sucrose gradient.
- Spin in mini-ultracentrifuge, 45K, 20(C, 4 hours (no brake).
- Collect fractions by puncturing the bottom of the gradient tube with a 20G needle and allowing the sucrose to flow through the needle. Collect the first 20 drops in a Falcon 2059 tube then collect 10 l-drop fractions (labelled 1-10). Each drop is about 60 (l in volume.
- Run 5 (l of each fraction on a 0.8% agarose gel to check the size.
- Pool fractions 1-4 (about 10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb).
- Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- Spin in microfuge, high speed, 30 minutes.
- Wash with 1 ml 70% ethanol.
- Spin in microfuge, high speed, 10 minutes and dry.
- Resuspend each in 10 (l TE buffer.
- Test Ligation to Lambda Arms
- Plate assay to get an approximate concentration. Spot 0.5 (l of the sample on agarose containing ethidium bromide along with standards (DNA samples of known concentration). View in UV light and estimate concentration compared to the standards. Fraction 1-4=>1.0 (g/(l. Fraction 5-7=500 ng/(l.
- Prepare the following ligation reactions (5 (l reactions) and incubate 4(C, overnight:
T4 DNA 10× Lambda Ligase Ligase 10 mM arms Insert (4 Sample H2O Buffer rATP (ZAP) DNA Wu/(1) Fraction 1-4 0.5 0.5 0.5 1.0 2.0 0.5 (1 (1 (1 (1 (1 (1 Fraction 5-7 0.5 0.5 0.5 1.0 2.0 0.5 (1 (1 (1 (1 (1 (1 - Test Package and Plate
- Package the ligation reactions following manufacturer's protocol. Stop packaging reactions with 500 (l SM buffer and pool packaging that came from the same ligation.
- Titer 1.0 (l of each on appropriate host (OD 600=1.0) [XLI-Blue MRF]
- Add 200 (l host (in mM MgSO 4) to Falcon 2059 tubes
- Inoculate with 1 (l packaged phage
- Incubate 37(C, 15 minutes
- Add about 3 ml 48(C top agar
- [50ml stock containing 150 (l IPTG (0.5M) and 300 (l X-GAL (350 mg/ml)]
- Plate on 100mm plates and incubate 37(C, overnight.
- Amplification of Libraries (5.0×10 5 recombinants from each library)
- Add 3.0 ml host cells (OD 600=1.0) to two 50 ml conical tube.
- Inoculate with 2.5×10 5 pfu per conical tube.
- Incubate 37(C, 20 minutes.
- Add top agar to each tube to a final volume of 45 ml.
- Plate the tube across five 150 mm plates.
- Incubate 37(C, 6-8 hours or until plaques are about pin-head in size.
- Overlay with 8-10 ml SM Buffer and place at 4(C overnight (with gentle rocking if possible).
- Harvest Phage
- Recover phage suspension by pouring the SM buffer off each plate into a 50-ml conical tube.
- Add 3 ml chloroform, shake vigorously and incubate at room temperature, 15 minutes.
- Centrifuge at 2K rpm, 10 minutes to remove cell debris.
- Pour supernatant into a sterile flask, add 500 (l chloroform.
- Store at 4(C.
- Titer Amplified Library
- Make serial dilutions:
- 10 −5=1 (l amplified phage in 1 ml SM Buffer
- 10 −6=1 (l of the 10−3 dilution in 1 ml SM Buffer
- Add 200 (l host (in 10 mM MgSO 4) to two tubes.
- Inoculate one with 10 (
l 10−6 dilution (10−6). - Inoculate the other with 1 (
l 10−6 dilution (10−6) - Incubate 37(C, 15 minutes.
- Add about 3 ml 48(C top agar.
- [50 ml stock containing 150 (l IPTG (0.5M) and 375 (l X-GAL (350 mg/ml)]
- Plate on 100 mm plates and incubate 37(C, overnight.
- Excise the ZAP II library to create the pBluescript library according to manufacturers protocols (Stratagene).
- Prior to library generation, purified DNA can be normalized. DNA is first fractionated according to the following protocol:
- Sample composed of genomic DNA is purified on a cesium-chloride gradient. The cesium chloride (Rf=1.3980) solution is filtered through a 0.2 (m filter and 15 ml is loaded into a 35 ml OptiSeal tube (Beckman). The DNA is added and thoroughly mixed. Ten micrograms of bis-benzimide (Sigma; Hoechst 33258) is added and mixed thoroughly. The tube is then filled with the filtered cesium chloride solution and spun in a VTi50 rotor in a Beckman L8-70 Ultracentrifuge at 33,000 rpm for 72 hours.
- Following centrifugation, a syringe pump and fractionator (Brandel Model 186) are used to drive the gradient through an ISCO UA-5 UV absorbance detector set to 280 nm. Peaks representing the DNA from the organisms present in an environmental sample are obtained. Eubacterial sequences can be detected by PCR amplification of DNA encoding rRNA from a 10-fold dilution of the E. coli peak using the following primers to amplify:
- Forward primer:
Forward primer: 5′-AGAGTTTGATCCTGGCTCAG-3′ Reverse primer: 5′-GGTTACCTTGTTACGACTT-3′ - Recovered DNA is sheared or enzymatically digested to 3-6 kb fragments. Lone-linker primers are ligated and the DNA is sized selected. Size-selected DNA is amplified by PCR, if necessary.
- Normalization is then accomplished as follows:
- Double-stranded DNA sample is resuspended in hybridization buffer (0.12 M NaH 2PO4, pH 6.8/0.82 M NaCl/1 mM EDTA/0.1% SDS).
- Sample is overlaid with mineral oil and denatured by boiling for 10 minutes.
- Sample is incubated at 68(C for 12-36 hours.
- Double-stranded DNA is separated from single-stranded DNA according to standard protocols (Sambrook, 1989) on hydroxyapatite at 60(C.
- The single-stranded DNA fraction is desalted and amplified by PCR.
- The process is repeated for several more rounds (up to 5 or more).
- Gene libraries, including those generated as described in Example 1, can be screened for bioactivities of interest on a FACS machine as indicated herein. A screening process begins with staining of the cells with a desirable substrate according to the following example.
- A gene library is made from the hyperthermophilic archaeon Sulfulobus solfataricus in the (-ZAPII vector according to the manufacturers instructions (Stratagene Cloning Systems, Inc., La Jolla, Calif.), and excised into the pBluescript plasmid according to the manufacturers instructions (Stratagene) . DNA was isolated using the IsoQuick DNA isolation kit according to the manufacturers instructions (Orca, Inc., Bothell, Wash.).
- To screen for (-galactosidase activity, cells are stained as follows:
- Cells are cultivated overnight at 37(C in an orbital shaker at 250rpm
- Cells are centrifuged to collect about 2×10 7 cells (0.1 ml of the culture)
- Cells are resuspended in 1 ml of deionized water, and stained with C 12-Fluoroscein-Di-(-D-galactopyranoside (FDG) as follows:
0.5 ml Cells 50 (l C12-FDG staining solution (1 mg C12-FDG in 1 ml of a mixture of 98% H2O, 1% DMSO, 1% EtOH) 50 (l Propidium iodide (PI) staining solution (50 (g/ml of distilled water) - Sample is incubated in the dark at 37(C with shaking at 150 rpm for 30 minutes.
- Cells are then heated to 70(C for 30 minutes (this step can be avoided if sample is not derived from a hyperthermophilic organism).
- The excised (-ZAP II library is incubated for 2 hours and induced with IPTG. Cells are centrifuged, washed and stained with the desired enzyme substrate, for example C 12-Fluoroscein-Di-(-D-galactopyranoside (FDG) as in Example 3. Clones are sorted on a commercially available FACS machine, and positives are collected. Cells are lysed according to standard techniques (Current Protocols in Molecular Biology, 1987) and plasmids are transformed into new host by electroporation using standard techniques. Transformed cells are plated for secondary screening. The procedure is illustrated in FIG. 5.
- Sorted organisms can be grown and plated for secondary screening.
- Cells can be sorted in a FACS instrument directly on microtiter plates in accordance with the present invention. Sorting in this fashion facilitates downstream processing of positive clones.
- E. coli cells containing (-galactosidase genes are exposed to a staining solution in accordance with Example 3. These cells are then left to sit on ice for three minutes. For the cell sorting procedure they are diluted 1:100 in deionized water or in Phospate Buffered Saline buffer solution according to the manufacturers protocols for cell sorting. The cells are then sorted by the FACS instrument into microtiter plates, one cell per well. The sorting criteria is fluorescein fluorescence indicating (-galactosidase activity or PI for indicating the staining of dead cells (unlike viable cells, dead cells have no membrane potential; hence PI remains in the cell with dead cells and is pumped out with live cells) . Results as observed on the microtiter plate are shown in FIG. 6.
- Alting-Mees, M. A., Short J. M., Nucl. Acids. Res. 1989, 17, 9494.
- Hay, B. and Short, J. Strategies, 1992, 5, 16.
- Enzyme Systems Products, Dublin Calif. 94568; Molecular Probes, Eugene, Oreg. 97402, Peninsula Laboratories, Belmont, Calif. 94002.
- Adams, M. W. W., Kelly, R. M., Chemical and Engineering News, Dec. 18, 1995,
- Amann, R., Ludwig, W., and Schleifer, K.-H. Microbiological Reviews, 1995, 59, 143.
- Barnes, S. M., Fundyga, R. E., Jeffries, M. W. and Pace, N. R. Proc. Nat. Acad. Sci. USA , 1994, 91, 1609.
- Bateson M. M., Wiegel, J., Ward, D. M., System. Appl. Microbiol. 1989, 12, 1-7
- Betz, J. W., Aretz, W., Hartel, W., Cytometry, 1984, 5, 145-150
- Davey, H. M., Kell, D. B., Microbiological Reviews, 1996, 60, 4, 641-696
- Diaper, J. P., Edwards, C., J. Appl. Bacteriol., 1994, 77, 221-228
- Enzyme Nomenclature , Academic Press: NY, 1992.
- Faber, Biotransformation in organic chemistry 2nd edition, Springer Verlag, 1995.
- Faber, U.S. Tonkovich and Gerber, Dept. of Energy Study, 1995.
- Fiering, S. N., Roeder, M., Nolan, G. P., Micklem, D. R., Parcks, D. R., Herzenberg, L. A. Cytometry, 1991, 12, 291-301.
- Giovannoni, S. J., Britschgi, T. B., Mover, C. L., Field, K. G., Nature, 1990 345, 60-63
- Murray, M. G., and Thompson, W. F., Nucl. Acids Res., 1980, 8, 4321-4325
- Nolan, G. P., Fiering, S., Nicolas, J., F., Herzenberg, L. A., Proc. Natl. Acad. Sci. USA, 1988, 85, 2603-2607.
- Plovins A., Alvarez A. M., Ibanez M., Molina M., Nombela C., Appl. Environ. Microbiol., 1994, 60, 4638-4641.
- Short, J. M., Fernandez, J. F. Sorge, J. A., and Huse, W. Nucleic Acids Res., 1988,16 , 7583-7600.
- Short, J. M., and Sorge, J. A. Methods in Enzymology, 1992, 216, 495-508.
- Tonkovich, A., L., Gerber, M. A., US Department of Energy, Office of Industrial Technology, Biological and Chemical Technologies Research Program under contract DE-AC06-76RLO 1830
- Torvsik, V. Goksoyr, J. Daae, F. L., Appl. and Environm. Microbiol. 1990, 56, 782-787
- Wittrup, K. D., Bailey, J. E., Cytometry, 1988, 9, 394-404.
- Wrotnowski, Genetic Engeneering News, Feb. 1, 1997.
TABLE 1 Habitat Cultured (%) Seawater 0.001-1.0 Freshwater 0.25 Mesotrophic lake 0.01-1.0 Unpolluted esturine 0.1-3.0 waters Activated sludge 1.0-15.0 Sediments 0.25 Soil 0.3
Claims (18)
1. A method for high throughput screening of prokaryotic genomic DNA samples to identify one or more enzymes encoded by the prokaryotic DNA of said sample, comprising the steps of :
a) generating a normalized, multispecific, prokaryotic expression library;
b) inserting bioactive substrates into samples of the library;
c) screening the samples with a fluorescent analyzer that detects bioactive fluorescence;
d) separating samples detected as positive for bioactive fluorescence; and
e) determining the DNA sequence of positive samples;
wherein the DNA sequence identifies and encodes an enzyme that catalyzes the bioactive substrate detected in step d).
2. The method of claim 1 , wherein the enzyme is selected from the group consisting of lipases, esterases, proteases, glycosidases, glycosyl transferases, phosphatases, kinases, mono- and dioxygenases, haloperoxidases, lignin peroxidases, diarylpropane peroxidases, epozide hydrolases, nitrile hydratases, nitrilases, transaminases, amidases, and acylases.
3. The method of claim 1 , wherein the prokaryotic expression library contains at least of about 2×106 clones.
4. The method of claim 1 , wherein the sample is a prokaryotic cell.
5. The method of claim 4 , wherein the prokaryotic cell is gram negative.
6. The method of claim 1 , wherein the sample is encapsulated in a gel microdrop.
7. The method of claim 1 , wherein the high-throughput screening step c) screens up to about 35 million samples per hour.
8. The method of claim 1 , wherein the prokaryotic expression library contains extremophiles.
9. The method of claim 3 , wherein the extremophiles are thermophiles.
10. The method of claim 3 , wherein the extremeophiles are selected from the group consisting of hyperthermophiles, psychrophiles, halophiles, psychrotrophs, alkalophiles, and acidophiles.
11. The method of claim 1 , wherein the bioactive substrate comprises C12FDG.
12. The method of claim 10 , wherein the bioactive substrate further comprises a lipophilic tail.
13. The method of claim 1 , wherein the the samples are heated before step b).
14. The method of claim 13 , wherein the heating is in the range of about 70° C.
15. The method of claim 14 , wherein the heating occurs in the range of about 30 minutes.
16. The method of claim 1 , wherein the fluorescent analyzer comprises a FACS apparatus.
17. The method of claim 1 , wherein the prokaryotic expression library is biopanned before step b).
18. The method of claim 1 , including the additional steps of:
subjecting an enzyme encoded by the DNA identified in step d) to directed evolution comprising the steps of:
a) subjecting the enzyme to non-directed mutagenesis; and
b) screening mutant enzymes produced in step a) for a mutant enzyme that is stable at a temperature of at least in the range of about 60° C. and that has functioning enzymatic activity at a temperature at least 10° C. below its optimal temperature range and that catalyzes a greater amount of a catalytic substrate per a defined unit of time than the enzyme of step a).
Priority Applications (37)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/876,276 US20030215798A1 (en) | 1997-06-16 | 1997-06-16 | High throughput fluorescence-based screening for novel enzymes |
| EP98931354A EP1009858A4 (en) | 1997-06-16 | 1998-06-16 | High throughput screening for novel enzymes |
| CA002294380A CA2294380A1 (en) | 1997-06-16 | 1998-06-16 | High throughput screening for novel enzymes |
| US09/098,206 US6174673B1 (en) | 1997-06-16 | 1998-06-16 | High throughput screening for novel enzymes |
| AU81502/98A AU749587B2 (en) | 1997-06-16 | 1998-06-16 | High throughput screening for novel enzymes |
| PCT/US1998/012674 WO1998058085A1 (en) | 1997-06-16 | 1998-06-16 | High throughput screening for novel enzymes |
| JP50478299A JP2002505590A (en) | 1997-06-16 | 1998-06-16 | High-throughput screening of novel enzymes |
| US09/444,112 US6972183B1 (en) | 1997-06-16 | 1999-11-22 | Capillary array-based enzyme screening |
| US09/687,219 US6794127B1 (en) | 1997-06-16 | 2000-10-12 | Capillary array-based sample screening |
| US09/738,871 US20010041333A1 (en) | 1997-06-16 | 2000-12-15 | High throughput screening for a bioactivity or biomolecule |
| US09/790,321 US20020048809A1 (en) | 1997-06-16 | 2001-02-21 | Capillary array-based sample screening |
| US09/848,083 US6602675B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening of mycelia for bioactivities or biomolecules |
| US09/848,185 US20020127560A1 (en) | 1997-06-16 | 2001-05-03 | High throughput screening for novel enzymes |
| US09/848,651 US6806048B2 (en) | 1997-06-16 | 2001-05-03 | Method for high throughput screening of an environmental library |
| US09/848,095 US6872526B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening for novel Bioactivities |
| US09/894,956 US20020015997A1 (en) | 1997-06-16 | 2001-06-27 | Capillary array-based sample screening |
| US09/975,036 US20030049841A1 (en) | 1997-06-16 | 2001-10-10 | High throughput or capillary-based screening for a bioactivity or biomolecule |
| US10/084,552 US7019827B2 (en) | 1997-06-16 | 2002-02-25 | GigaMatrix holding tray having through-hole wells |
| US10/095,907 US20020102598A1 (en) | 1997-06-16 | 2002-03-11 | Positioning system for moving a selected station of a holding plate to a predetermined location for interaction with a probe |
| US10/096,701 US20020150949A1 (en) | 1997-06-16 | 2002-03-12 | High throughput screening for novel enzymes |
| US10/145,314 US20030092022A1 (en) | 1997-06-16 | 2002-05-13 | High throughput screening for sequences of interest |
| US10/145,280 US20030077620A1 (en) | 1997-06-16 | 2002-05-13 | High throughput screening for sequences of interest |
| US10/145,281 US20030077677A1 (en) | 1997-06-16 | 2002-05-13 | High throughput screening for sequences of interest |
| US10/151,469 US20030219752A1 (en) | 1995-12-07 | 2002-05-17 | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US10/156,878 US20030096220A1 (en) | 1997-06-16 | 2002-05-28 | Capillary array-based sample screening |
| US10/157,653 US6866824B2 (en) | 1997-06-16 | 2002-05-28 | Capillary array-based sample screening |
| US10/232,869 US20030003500A1 (en) | 1997-06-16 | 2002-08-30 | Capillary array-based sample screening |
| US10/237,247 US20030083575A1 (en) | 1997-06-16 | 2002-09-04 | Capillary array-based sample screening |
| US10/237,246 US20030013115A1 (en) | 1997-06-16 | 2002-09-04 | Capillary array-based sample screening |
| US10/286,194 US20030054543A1 (en) | 1997-06-16 | 2002-11-01 | Device for moving a selected station of a holding plate to a predetermined location for interaction with a probe |
| US10/506,930 US20050118707A1 (en) | 1997-06-16 | 2003-03-11 | Positioning system for moving a selected station of a holding plate to a predetermined location for interaction with a probe |
| US10/626,477 US20050070005A1 (en) | 1997-06-16 | 2003-07-23 | High throughput or capillary-based screening for a bioactivity or biomolecule |
| US10/688,057 US20040241759A1 (en) | 1997-06-16 | 2003-10-17 | High throughput screening of libraries |
| US10/842,187 US20050069917A1 (en) | 1997-06-16 | 2004-05-10 | High throughput screening for novel enzymes |
| US10/948,807 US20050040550A1 (en) | 1997-06-16 | 2004-09-23 | High throughput screening for novel bioactivities |
| US10/960,137 US20050064498A1 (en) | 1997-06-16 | 2004-10-07 | High throughput screening for sequences of interest |
| US10/964,940 US20050046833A1 (en) | 1997-06-16 | 2004-10-14 | Gigamatrix holding tray having through-hole wells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/876,276 US20030215798A1 (en) | 1997-06-16 | 1997-06-16 | High throughput fluorescence-based screening for novel enzymes |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/012239 Continuation-In-Part WO1998001581A1 (en) | 1996-07-09 | 1997-07-09 | Method of dna shuffling with polynucleotides produced by blockingor interrupting a synthesis or amplification process |
| US09/098,206 Continuation-In-Part US6174673B1 (en) | 1995-12-07 | 1998-06-16 | High throughput screening for novel enzymes |
| US09/444,112 Continuation-In-Part US6972183B1 (en) | 1995-12-07 | 1999-11-22 | Capillary array-based enzyme screening |
| US10/151,469 Continuation-In-Part US20030219752A1 (en) | 1995-12-07 | 2002-05-17 | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030215798A1 true US20030215798A1 (en) | 2003-11-20 |
Family
ID=25367333
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/876,276 Abandoned US20030215798A1 (en) | 1995-12-07 | 1997-06-16 | High throughput fluorescence-based screening for novel enzymes |
| US09/098,206 Expired - Lifetime US6174673B1 (en) | 1995-12-07 | 1998-06-16 | High throughput screening for novel enzymes |
| US09/848,185 Abandoned US20020127560A1 (en) | 1995-12-07 | 2001-05-03 | High throughput screening for novel enzymes |
| US09/848,651 Expired - Lifetime US6806048B2 (en) | 1997-06-16 | 2001-05-03 | Method for high throughput screening of an environmental library |
| US09/848,083 Expired - Lifetime US6602675B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening of mycelia for bioactivities or biomolecules |
| US09/848,095 Expired - Lifetime US6872526B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening for novel Bioactivities |
| US10/096,701 Abandoned US20020150949A1 (en) | 1997-06-16 | 2002-03-12 | High throughput screening for novel enzymes |
| US10/842,187 Abandoned US20050069917A1 (en) | 1997-06-16 | 2004-05-10 | High throughput screening for novel enzymes |
| US10/948,807 Abandoned US20050040550A1 (en) | 1997-06-16 | 2004-09-23 | High throughput screening for novel bioactivities |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/098,206 Expired - Lifetime US6174673B1 (en) | 1995-12-07 | 1998-06-16 | High throughput screening for novel enzymes |
| US09/848,185 Abandoned US20020127560A1 (en) | 1995-12-07 | 2001-05-03 | High throughput screening for novel enzymes |
| US09/848,651 Expired - Lifetime US6806048B2 (en) | 1997-06-16 | 2001-05-03 | Method for high throughput screening of an environmental library |
| US09/848,083 Expired - Lifetime US6602675B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening of mycelia for bioactivities or biomolecules |
| US09/848,095 Expired - Lifetime US6872526B2 (en) | 1997-06-16 | 2001-05-03 | High throughput screening for novel Bioactivities |
| US10/096,701 Abandoned US20020150949A1 (en) | 1997-06-16 | 2002-03-12 | High throughput screening for novel enzymes |
| US10/842,187 Abandoned US20050069917A1 (en) | 1997-06-16 | 2004-05-10 | High throughput screening for novel enzymes |
| US10/948,807 Abandoned US20050040550A1 (en) | 1997-06-16 | 2004-09-23 | High throughput screening for novel bioactivities |
Country Status (6)
| Country | Link |
|---|---|
| US (9) | US20030215798A1 (en) |
| EP (1) | EP1009858A4 (en) |
| JP (1) | JP2002505590A (en) |
| AU (1) | AU749587B2 (en) |
| CA (1) | CA2294380A1 (en) |
| WO (1) | WO1998058085A1 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030165955A1 (en) * | 2002-01-22 | 2003-09-04 | Suich Daniel J. | Fluorogenic dyes |
| US20060128033A1 (en) * | 2003-01-21 | 2006-06-15 | Chiron Corporation | Fluorogenic dyes |
| US20060147937A1 (en) * | 1999-11-23 | 2006-07-06 | Chromocell Corporation | Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences |
| US20090106853A1 (en) * | 2004-02-18 | 2009-04-23 | Kambiz Shekdar | Methods and materials using signaling probes |
| WO2011017288A1 (en) | 2009-08-05 | 2011-02-10 | Chromocell Corporation | Improved plants, microbes, and organisms |
| US8697383B2 (en) | 2010-05-25 | 2014-04-15 | Mitsubishi Rayon Co., Ltd. | Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme |
| US8945848B2 (en) | 2009-07-31 | 2015-02-03 | Chromocell Corporation | Methods and compositions for identifying and validating modulators of cell fate |
| US9051597B2 (en) | 2010-05-25 | 2015-06-09 | Mitsubishi Rayon Co., Ltd. | Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme |
| WO2015200501A1 (en) * | 2014-06-24 | 2015-12-30 | The Scripps Research Institute | Strain prioritization for natural product discovery by a high throughput real-time pcr method |
| US10227583B2 (en) | 2016-12-12 | 2019-03-12 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| CN113083383A (en) * | 2021-03-18 | 2021-07-09 | 华中农业大学 | Microfluidic chip device, preparation method and soil microbial community culture method |
| US11156626B2 (en) | 2016-12-30 | 2021-10-26 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| CN114028618A (en) * | 2021-10-25 | 2022-02-11 | 广东普洛宇飞生物科技有限公司 | Biological material based on amniotic membrane basement membrane and preparation method and application thereof |
| US11473081B2 (en) | 2016-12-12 | 2022-10-18 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US12318775B2 (en) | 2018-12-06 | 2025-06-03 | xCella Biosciences, Inc. | Lateral loading of microcapillary arrays |
Families Citing this family (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US20030215798A1 (en) * | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US7883872B2 (en) * | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
| US5811381A (en) * | 1996-10-10 | 1998-09-22 | Mark A. Emalfarb | Cellulase compositions and methods of use |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| CA2276064C (en) | 1997-01-17 | 2013-12-17 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
| US20040241759A1 (en) * | 1997-06-16 | 2004-12-02 | Eileen Tozer | High throughput screening of libraries |
| US20050070005A1 (en) * | 1997-06-16 | 2005-03-31 | Martin Keller | High throughput or capillary-based screening for a bioactivity or biomolecule |
| EP2270234B1 (en) | 1997-12-08 | 2013-03-06 | California Institute of Technology | Method for creating polynucleotide and polypeptide sequences |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US6740497B2 (en) * | 1998-03-06 | 2004-05-25 | The Regents Of The University Of California | Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility |
| US6461813B2 (en) | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
| WO1999054494A2 (en) * | 1998-04-17 | 1999-10-28 | Rigel Pharmaceuticals, Inc. | Multiparameter facs assays to detect alterations in cellular parameters |
| US8334238B2 (en) | 1998-04-17 | 2012-12-18 | Rigel, Inc. | Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries |
| US6897031B1 (en) | 1998-04-17 | 2005-05-24 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in exocytosis |
| CN1314911A (en) | 1998-05-01 | 2001-09-26 | 麦克西根股份有限公司 | Optimization of pest resistance genes using DNA shuffling |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US6605430B1 (en) | 1998-08-12 | 2003-08-12 | Maxygen, Inc. | DNA shuffling of monooxygenase genes for production of industrial chemicals |
| CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
| WO2000028018A1 (en) | 1998-11-10 | 2000-05-18 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes |
| US20020090612A1 (en) * | 1999-01-08 | 2002-07-11 | Jonathan M. Rothberg | Method of identifying nucleic acids |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| AU3210100A (en) | 1999-01-19 | 2000-08-01 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
| JP3399518B2 (en) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Semiconductor structure and method of manufacturing the same |
| AU3719500A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
| US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
| US7270969B2 (en) * | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
| US7803765B2 (en) * | 1999-05-05 | 2010-09-28 | Phylogica Limited | Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
| CA2721199A1 (en) * | 1999-05-05 | 2000-11-16 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| WO2001032858A1 (en) * | 1999-11-05 | 2001-05-10 | Novozymes A/S | A high throughput screening (hts) method |
| AU7646000A (en) * | 1999-11-05 | 2001-05-14 | Novozymes A/S | Methods to screen microorganisms or gene libraries for products secreted from a cell |
| US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
| US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| SG121902A1 (en) * | 2000-01-11 | 2006-05-26 | Maxygen Inc | Integrated systems for diversity generation and screening |
| AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| EP1276861A2 (en) * | 2000-03-24 | 2003-01-22 | Maxygen, Inc. | Methods for modulating cellular and organismal phenotypes |
| US20010047029A1 (en) * | 2000-04-26 | 2001-11-29 | Handelsman Jo E. | Triaryl cation antibiotics from environmental DNA |
| EP1360290A2 (en) | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| US7074590B2 (en) * | 2000-06-23 | 2006-07-11 | Maxygen, Inc. | Chimeric promoters |
| US20020072097A1 (en) * | 2000-07-07 | 2002-06-13 | Delcardayre Stephen | Molecular breeding of transposable elements |
| US6858422B2 (en) | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
| AU2001284997A1 (en) * | 2000-08-24 | 2002-03-04 | Maxygen, Inc. | Constructs and their use in metabolic pathway engineering |
| MXPA02005717A (en) * | 2000-10-10 | 2003-10-14 | Diversa Corp | High throughput or capillary-based screening for a bioactivity or biomolecule. |
| AU2002249116A1 (en) * | 2001-01-11 | 2002-09-19 | Lion Bioscience Ag | Gene library for screening methods |
| WO2002068678A2 (en) * | 2001-01-12 | 2002-09-06 | The Regents Of The University Of California | Beta-lactamase substrates having phenolic ethers |
| AU2002227883A1 (en) | 2001-01-25 | 2002-08-06 | Evolva Biotech A/S | A library of a collection of cells |
| US8008459B2 (en) * | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
| AU2002314820B2 (en) * | 2001-05-26 | 2008-01-24 | One Cell Systems, Inc. | Secretion of Molecules by Encapsulated Cells |
| EP1578987A2 (en) * | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| DE10146572A1 (en) * | 2001-09-21 | 2003-04-10 | Basf Ag | Process for the production of a normalized gene bank from nucleic acid extracts from soil samples and their use |
| US7026111B2 (en) | 2001-10-15 | 2006-04-11 | Beckman Coulter, Inc. | Methods and reagents for improved cell-based assays |
| GB0125043D0 (en) * | 2001-10-17 | 2001-12-12 | Biotica Tech Ltd | Production, detection and use of transformant cells |
| US20040137547A1 (en) * | 2001-12-28 | 2004-07-15 | Medtronic Minimed, Inc. | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
| EP1472349B1 (en) * | 2002-01-25 | 2008-10-29 | Evolva AG | Methods for multiple parameter screening and evolution of cells to produce small molecules with multiple functionalities |
| US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
| US20030166010A1 (en) * | 2002-02-25 | 2003-09-04 | Affholter Joseph A. | Custom ligand design for biomolecular filtration and purification for bioseperation |
| AU2002248051A1 (en) * | 2002-04-09 | 2003-12-19 | Genofocus Co., Ltd. | Stabilized biocatalysts and methods of bioconversion using the same |
| ATE527366T1 (en) * | 2002-08-01 | 2011-10-15 | Evolva Ltd | METHOD FOR MIXING MANY HETEROLOGUE GENES |
| EP2275536A1 (en) | 2002-08-06 | 2011-01-19 | Verdia, Inc. | AP1 amine oxidase variants |
| WO2004018673A2 (en) | 2002-08-20 | 2004-03-04 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Isolation and cloning of dna from uncultivated organisms |
| WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US20040091932A1 (en) * | 2002-11-13 | 2004-05-13 | Nutsibidze Nugzar N. | Method for producing from microbial sources enzymes having multiple improved characteristics |
| EP1601781B1 (en) * | 2003-03-10 | 2008-07-16 | The Johns Hopkins University | Method and apparatus for environmental monitoring and bioprospecting |
| US7041481B2 (en) | 2003-03-14 | 2006-05-09 | The Regents Of The University Of California | Chemical amplification based on fluid partitioning |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307403D0 (en) * | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| WO2004097027A2 (en) * | 2003-04-25 | 2004-11-11 | Dow Global Technologies Inc. | Screening of biocatalysts in plants |
| CA2521284C (en) | 2003-04-29 | 2014-07-08 | Pioneer Hi-Bred International, Inc. | Novel glyphosate-n-acetyltransferase (gat) genes |
| US7960148B2 (en) | 2003-07-02 | 2011-06-14 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
| WO2005012550A2 (en) * | 2003-07-31 | 2005-02-10 | Diversa Corporation | Screening methods and libraries of trace amounts of dna from uncultivated microorganisms |
| EP1677886A1 (en) * | 2003-09-30 | 2006-07-12 | Chromba, Inc. | Multicapillary column for chromatography and sample preparation |
| US20070017870A1 (en) * | 2003-09-30 | 2007-01-25 | Belov Yuri P | Multicapillary device for sample preparation |
| US20050221339A1 (en) * | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| DK1754052T3 (en) * | 2004-06-03 | 2015-09-28 | Phylogica Ltd | Modulators with biochemical properties |
| WO2005121336A1 (en) * | 2004-06-08 | 2005-12-22 | Toagosei Co., Ltd. | Method of purifying environmental dna and method of efficiently screening protein-encoding gene from environmental dna |
| US20080070291A1 (en) * | 2004-06-16 | 2008-03-20 | David Lam | Compositions and Methods for Enzymatic Decolorization of Chlorophyll |
| JP2008505619A (en) | 2004-06-16 | 2008-02-28 | ヴェレニウム コーポレイション | Compositions and methods for enzymatic decolorization of chlorophyll |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| US20090038023A1 (en) | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| CN102943085A (en) | 2005-03-15 | 2013-02-27 | 维莱尼姆公司 | Cellulases, nucleic acids encoding them and methods for making and using them |
| ES2439709T3 (en) | 2005-06-21 | 2014-01-24 | Xoma (Us) Llc | Antibodies and fragments thereof that bind to IL-1beta |
| EP2363205A3 (en) | 2006-01-11 | 2014-06-04 | Raindance Technologies, Inc. | Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors |
| MY160756A (en) | 2006-02-10 | 2017-03-15 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
| EP1989302B1 (en) | 2006-02-14 | 2018-04-11 | BP Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
| DK1987178T3 (en) * | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
| EP2112227B1 (en) | 2006-03-07 | 2013-05-15 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
| EP3153580A3 (en) | 2006-03-07 | 2017-04-19 | BASF Enzymes LLC | Aldolases, nucleic acids encoding them and methods for making and using them |
| WO2007123676A1 (en) * | 2006-03-28 | 2007-11-01 | Advanced Analytical Technologies, Inc. | Rapid detection of mold by accelerated growth and detection |
| EP3782722B1 (en) | 2006-05-11 | 2022-07-06 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| MX369001B (en) | 2006-08-04 | 2019-10-24 | Basf Enzymes Llc | Glucanases, nucleic acids encoding them and methods for making and using them. |
| EP3536396B1 (en) | 2006-08-07 | 2022-03-30 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| US8063012B2 (en) * | 2006-09-19 | 2011-11-22 | Phylogica Limited | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor |
| US7807454B2 (en) | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
| US9862956B2 (en) | 2006-12-10 | 2018-01-09 | Danisco Us Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
| US8680252B2 (en) | 2006-12-10 | 2014-03-25 | Dyadic International (Usa), Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
| US20100189706A1 (en) * | 2007-01-30 | 2010-07-29 | Cathy Chang | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| WO2008147530A1 (en) * | 2007-05-24 | 2008-12-04 | The Regents Of The University Of California | Integrated fluidics devices with magnetic sorting |
| US8822409B2 (en) * | 2007-06-20 | 2014-09-02 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith |
| US8551751B2 (en) * | 2007-09-07 | 2013-10-08 | Dyadic International, Inc. | BX11 enzymes having xylosidase activity |
| CN103757036B (en) | 2007-10-03 | 2019-10-01 | 维莱尼姆公司 | Zytase, the nucleic acid and its methods for making and using same for encoding them |
| WO2009088949A1 (en) | 2008-01-03 | 2009-07-16 | Verenium Corporation | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
| EP2274098B1 (en) * | 2008-03-28 | 2013-12-25 | Biotix, Inc. | Multicapillary sample preparation devices and methods for processing analytes |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| EP3415235B1 (en) | 2009-03-23 | 2025-11-12 | Bio-Rad Laboratories, Inc. | Manipulation of microfluidic droplets |
| WO2010144745A2 (en) * | 2009-06-10 | 2010-12-16 | Cynvenio Biosystems, Inc. | Sheath flow devices and methods |
| EP2486409A1 (en) | 2009-10-09 | 2012-08-15 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| US9341609B2 (en) | 2010-02-08 | 2016-05-17 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Methods and systems for ultra-trace analysis of liquids |
| US8338182B2 (en) * | 2010-02-08 | 2012-12-25 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Methods and systems for fluid examination and remediation |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| JP5934657B2 (en) | 2010-02-12 | 2016-06-15 | レインダンス テクノロジーズ, インコーポレイテッド | Digital specimen analysis |
| US9139842B2 (en) | 2010-08-13 | 2015-09-22 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeting sequences of interest to the chloroplast |
| US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| EP3859011A1 (en) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
| EP2675819B1 (en) | 2011-02-18 | 2020-04-08 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
| EP3216872B1 (en) | 2011-06-02 | 2020-04-01 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013116698A2 (en) * | 2012-02-02 | 2013-08-08 | Invenra, Inc. | High throughput screen for biologically active polypeptides |
| CA2872096A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| US20160053277A1 (en) | 2013-03-14 | 2016-02-25 | Pioneer Hi-Bred International, Inc. | Compositions Having Dicamba Decarboxylase Activity and Methods of Use |
| EP2970935A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
| AU2014318731A1 (en) * | 2013-09-11 | 2016-03-17 | Agenus Inc. | High throughput screening for biomolecules |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| EP3090063B1 (en) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Method for detection of latent retrovirus |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CN114015569A (en) | 2015-04-21 | 2022-02-08 | 通用自动化实验技术公司 | High resolution systems, kits, devices, and methods for high throughput microbiological applications |
| US10712356B2 (en) | 2015-04-21 | 2020-07-14 | General Automation Lab Technologies Inc. | Apparatus and method for picking biological sample |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CA3007635A1 (en) | 2015-12-07 | 2017-06-15 | Zymergen Inc. | Promoters from corynebacterium glutamicum |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| US10544390B2 (en) | 2016-06-30 | 2020-01-28 | Zymergen Inc. | Methods for generating a bacterial hemoglobin library and uses thereof |
| JP2019519241A (en) | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | Method for producing a glucose permease library and its use |
| EP3321352A1 (en) * | 2016-11-09 | 2018-05-16 | Biomillenia SAS | Auxotrophic selection system |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3574107A1 (en) * | 2017-01-26 | 2019-12-04 | Biomillenia SAS | High-throughput microfluidic screening in droplets |
| MX2019011579A (en) | 2017-03-28 | 2020-01-20 | Plantarc Bio Ltd | Methods for improving traits in plants. |
| EP3818153B1 (en) | 2018-07-06 | 2023-12-13 | The Regents Of The University Of Colorado | Genetically encoded system for constructing and detecting biologically active agents |
| KR102230151B1 (en) * | 2018-07-20 | 2021-03-22 | 한국생명공학연구원 | A screening system for formate dehydrogenase with increased carbon dioxide reducing activity and uses thereof |
| CA3167048A1 (en) * | 2020-01-08 | 2021-07-15 | The Regents Of The University Of Colorado, A Body Corporate | Discovery and evolution of biologically active metabolites |
| CN112686259B (en) * | 2020-12-16 | 2023-09-26 | 中国石油大学(北京) | Intelligent identification method, device and storage medium for rock images based on deep learning |
| CN118043458A (en) * | 2021-10-06 | 2024-05-14 | 图尔库大学 | Metabolic engineering of actinomycetes through single-cell mutant selection |
| US20250034551A1 (en) * | 2021-11-03 | 2025-01-30 | Think Bioscience, Inc. | Methods and systems for high-throughput biochemical screens |
| EP4516901A1 (en) | 2023-08-31 | 2025-03-05 | Vilnius University | A method for screening of hydrolytic enzymes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055390A (en) * | 1988-04-22 | 1991-10-08 | Massachusetts Institute Of Technology | Process for chemical manipulation of non-aqueous surrounded microdroplets |
| US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399219A (en) | 1981-01-29 | 1983-08-16 | Massachusetts Institute Of Technology | Process for isolating microbiologically active material |
| US4643968A (en) | 1981-01-29 | 1987-02-17 | Massachusetts Institute Of Technology | Process for determining metabolism and growth of cells under various conditions |
| SE441009B (en) | 1982-03-08 | 1985-09-02 | Kjell Nilsson | WAY TO IMMOBILIZE LIVING BIOMATERIAL IN PEARLY POLYMERS |
| US4801529A (en) * | 1985-06-18 | 1989-01-31 | Brandeis University | Methods for isolating mutant microoganisms using microcapsules coated with indicator material |
| US4916060A (en) | 1985-09-17 | 1990-04-10 | Massachusetts Institute Of Technology | Process for chemical measurement in small volume samples by fluorescent indicators |
| US5225332A (en) | 1988-04-22 | 1993-07-06 | Massachusetts Institute Of Technology | Process for manipulation of non-aqueous surrounded microdroplets |
| US4959301A (en) | 1988-04-22 | 1990-09-25 | Massachusetts Institute Of Technology | Process for rapidly enumerating viable entities |
| ATE256738T1 (en) * | 1992-10-30 | 2004-01-15 | Gen Hospital Corp | A NEW CELL CYCLE CONTROL PROTEIN |
| US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5663046A (en) * | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| AU723619B2 (en) * | 1995-04-24 | 2000-08-31 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
| US5958672A (en) * | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US6057103A (en) * | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
| US5968738A (en) * | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US20030215798A1 (en) * | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
| ATE260987T1 (en) * | 1995-12-07 | 2004-03-15 | Diversa Corp | METHOD FOR SCREENING ENZYMATIC ACTIVITY |
| US6803188B1 (en) * | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
| US5763239A (en) * | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| AU6571598A (en) * | 1997-03-18 | 1998-10-12 | Chromaxome Corporation | Methods for screening compounds using encapsulated cells |
| US5858367A (en) * | 1997-03-27 | 1999-01-12 | Case Western Reserve University | Methods for screening for antimicrobials utilizing AarC and compositions thereof |
| US6969584B2 (en) | 1997-06-12 | 2005-11-29 | Rigel Pharmaceuticals, Inc. | Combinatorial enzymatic complexes |
| US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
| WO1999054494A2 (en) | 1998-04-17 | 1999-10-28 | Rigel Pharmaceuticals, Inc. | Multiparameter facs assays to detect alterations in cellular parameters |
| US6391576B1 (en) | 1999-10-13 | 2002-05-21 | Japan Bioindustry Association | Method for isolating a microbe |
-
1997
- 1997-06-16 US US08/876,276 patent/US20030215798A1/en not_active Abandoned
-
1998
- 1998-06-16 JP JP50478299A patent/JP2002505590A/en not_active Ceased
- 1998-06-16 AU AU81502/98A patent/AU749587B2/en not_active Ceased
- 1998-06-16 CA CA002294380A patent/CA2294380A1/en not_active Abandoned
- 1998-06-16 US US09/098,206 patent/US6174673B1/en not_active Expired - Lifetime
- 1998-06-16 EP EP98931354A patent/EP1009858A4/en not_active Withdrawn
- 1998-06-16 WO PCT/US1998/012674 patent/WO1998058085A1/en not_active Ceased
-
2001
- 2001-05-03 US US09/848,185 patent/US20020127560A1/en not_active Abandoned
- 2001-05-03 US US09/848,651 patent/US6806048B2/en not_active Expired - Lifetime
- 2001-05-03 US US09/848,083 patent/US6602675B2/en not_active Expired - Lifetime
- 2001-05-03 US US09/848,095 patent/US6872526B2/en not_active Expired - Lifetime
-
2002
- 2002-03-12 US US10/096,701 patent/US20020150949A1/en not_active Abandoned
-
2004
- 2004-05-10 US US10/842,187 patent/US20050069917A1/en not_active Abandoned
- 2004-09-23 US US10/948,807 patent/US20050040550A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055390A (en) * | 1988-04-22 | 1991-10-08 | Massachusetts Institute Of Technology | Process for chemical manipulation of non-aqueous surrounded microdroplets |
| US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060147937A1 (en) * | 1999-11-23 | 2006-07-06 | Chromocell Corporation | Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences |
| US20100212040A1 (en) * | 1999-11-23 | 2010-08-19 | Chromocell Corporation | Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| US20030165955A1 (en) * | 2002-01-22 | 2003-09-04 | Suich Daniel J. | Fluorogenic dyes |
| US20060128033A1 (en) * | 2003-01-21 | 2006-06-15 | Chiron Corporation | Fluorogenic dyes |
| US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| US8916503B2 (en) * | 2004-02-18 | 2014-12-23 | Chromocell Corporation | Methods and materials using signaling probes |
| US20090106853A1 (en) * | 2004-02-18 | 2009-04-23 | Kambiz Shekdar | Methods and materials using signaling probes |
| US8945848B2 (en) | 2009-07-31 | 2015-02-03 | Chromocell Corporation | Methods and compositions for identifying and validating modulators of cell fate |
| US9657357B2 (en) | 2009-07-31 | 2017-05-23 | Chromocell Corporation | Methods and compositions for identifying and validating modulators of cell fate |
| WO2011017288A1 (en) | 2009-08-05 | 2011-02-10 | Chromocell Corporation | Improved plants, microbes, and organisms |
| US9051597B2 (en) | 2010-05-25 | 2015-06-09 | Mitsubishi Rayon Co., Ltd. | Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme |
| US8697383B2 (en) | 2010-05-25 | 2014-04-15 | Mitsubishi Rayon Co., Ltd. | Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme |
| WO2015200501A1 (en) * | 2014-06-24 | 2015-12-30 | The Scripps Research Institute | Strain prioritization for natural product discovery by a high throughput real-time pcr method |
| US10227583B2 (en) | 2016-12-12 | 2019-03-12 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US11473081B2 (en) | 2016-12-12 | 2022-10-18 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US12024705B2 (en) | 2016-12-12 | 2024-07-02 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US12228584B2 (en) | 2016-12-30 | 2025-02-18 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| US11156626B2 (en) | 2016-12-30 | 2021-10-26 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| US12318775B2 (en) | 2018-12-06 | 2025-06-03 | xCella Biosciences, Inc. | Lateral loading of microcapillary arrays |
| CN113083383A (en) * | 2021-03-18 | 2021-07-09 | 华中农业大学 | Microfluidic chip device, preparation method and soil microbial community culture method |
| CN114028618A (en) * | 2021-10-25 | 2022-02-11 | 广东普洛宇飞生物科技有限公司 | Biological material based on amniotic membrane basement membrane and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU749587B2 (en) | 2002-06-27 |
| US6602675B2 (en) | 2003-08-05 |
| WO1998058085A1 (en) | 1998-12-23 |
| US6174673B1 (en) | 2001-01-16 |
| JP2002505590A (en) | 2002-02-19 |
| US20020001809A1 (en) | 2002-01-03 |
| US20020127560A1 (en) | 2002-09-12 |
| US20010034040A1 (en) | 2001-10-25 |
| US20050040550A1 (en) | 2005-02-24 |
| US20050069917A1 (en) | 2005-03-31 |
| US20020150949A1 (en) | 2002-10-17 |
| EP1009858A4 (en) | 2001-03-07 |
| US6806048B2 (en) | 2004-10-19 |
| EP1009858A1 (en) | 2000-06-21 |
| CA2294380A1 (en) | 1998-12-23 |
| AU8150298A (en) | 1999-01-04 |
| US6872526B2 (en) | 2005-03-29 |
| US20010034031A1 (en) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030215798A1 (en) | High throughput fluorescence-based screening for novel enzymes | |
| AU741139B2 (en) | Screening for novel bioactivities | |
| US6168919B1 (en) | Screening methods for enzymes and enzyme kits | |
| US6632600B1 (en) | Altered thermostability of enzymes | |
| EP0839185A1 (en) | Screening methods for enzymes and enzyme kits | |
| EP1364052A2 (en) | High throughput or capillary-based screening for a bioactivity or biomolecule | |
| US6972183B1 (en) | Capillary array-based enzyme screening | |
| US20010041333A1 (en) | High throughput screening for a bioactivity or biomolecule | |
| US20060094033A1 (en) | Screening methods and libraries of trace amounts of DNA from uncultivated microorganisms | |
| AU777815B2 (en) | High throughput screening for novel enzymes | |
| US20050064498A1 (en) | High throughput screening for sequences of interest | |
| JP2002516679A (en) | Construction and Use of Cataloged Nucleic Acid Libraries Containing Advantageously Regulated Amounts of Specific Components | |
| CA2391626A1 (en) | Combinatorial screening of mixed populations of organisms | |
| AU2005200173A1 (en) | Screening for novel bioactivities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DIVERSA CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHORT, JAY M.;KELLER, MARTIN;REEL/FRAME:010476/0273;SIGNING DATES FROM 19991201 TO 19991207 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |